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ABSTRACT 
The aim of this thesis was to investigate the link between malignant lymphomas and 
chronic inflammation, in particular the associations between inflammatory activity, 
immune-modulatory treatment and risk of lymphoma development. To address this 
aim, we used Swedish population-based registers, mandatory cancer reporting and 
nation-wide clinical registers including the Swedish Rheumatology Register (SRQ).  
                                                                                                                                 
In study I we investigated whether patients with rheumatoid arthritis (RA) are at 
increased risk of lymphoma or cancer overall before clinical onset of RA, and if this risk 
increases with time since RA diagnosis. A cohort of 6,745 incident RA patients (1997-
2006) was identified using data from the SRQ. Each cohort member was matched to 
five population comparator subjects. Relative risks of lymphoma and cancer overall 
before and after diagnosis of RA were estimated. We observed no increased risks 
before diagnosis of RA whereas during the first ten years following diagnosis, the 
lymphoma risk was almost doubled with a non-significant trend of increasing risks 
with longer RA disease duration.  
In study II with a larger study population and with longer follow-up, we set out to 
assess whether the lymphoma risk remains elevated in RA patients diagnosed in the 
last few years and to explore potential risk predictors in relation to disease 
characteristics and therapy, focusing on the first year following RA diagnosis. Through 
SRQ, a cohort of 10,367 incident RA patients (1997-2010) was assembled. Each patient 
was matched to five population comparator subjects. The risk of lymphoma in 
recently diagnosed RA patients remained increased to the same magnitude as that 
reported from historical RA cohorts without any change in risk in recent years. The 
results indicated that inflammatory activity during the 1st year following RA diagnosis 
correlated with higher lymphoma risk, whereas oral glucocorticoids were associated 
with a reduced risk. Exposure to tumor necrosis factor inhibitor (TNFi) during the 
study period was not associated with increased lymphoma risk. Through 
histopathological classification, we further noted an increased proportion of Hodgkin 
lymphoma and diffuse large B-cell lymphoma and a decreased proportion of chronic 
lymphocytic leukemia in RA patients compared with the general population. 
In study III the relationship between treatment with glucocorticoids and lymphoma 
risk in RA patients was investigated in a case-control study. From a nationwide cohort 
of 74,651 prevalent RA patients 1964-1994, 378 RA patients with lymphoma and 378 
matched RA controls were identified. Different aspects of glucocorticoid treatment 
were abstracted from medical records. Treatment with glucocorticoids, oral as well as 
intra-articular, was associated with a reduced lymphoma risk.  
In study IV the underlying risks of lymphoma in patients with ankylosing spondylitis 
(AS) and psoriatic arthritis (PsA) were investigated, including risks in relation to 
disease characteristics and treatment. Nationwide prevalent cohorts of AS (n=8,707) 
and PsA (n=19,283) 2001-2010 were assembled. Each cohort member was matched to 
five population comparator subjects. On average, we observed no increased risks of 
lymphoma in AS or in PsA, although there was a risk increase in PsA patients treated 
with methotrexate and/or sulfasalazine. Based on small numbers there was no 
evidence of increased lymphoma incidence following therapy with TNFi in AS or in PsA 
patients.  
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1 INTRODUCTION 
The discipline of Rheumatology has changed dramatically over the last 10-15 years. 
Today we have the possibility to treat patients with rheumatoid arthritis (RA) and 
other inflammatory arthritis earlier and more efficiently than ever before. New 
therapies such as biological agents, increased knowledge on how to best use 
traditional therapies, as well as better assessment and control of disease activity, are 
all contributing factors. Nevertheless, much remains to be done. We need to learn 
more about long-term safety of these new therapies and to improve our knowledge 
on how to predict, and if possible to prevent the occurrence of different co- 
morbidities such as malignant lymphomas. 
 
The studies in this thesis investigate the link between malignant lymphoma and 
chronic inflammation with particular focus on inflammatory activity and immune-
modulatory therapy. In three of the studies, we focus on patients with rheumatoid 
arthritis. In the fourth, we study patients with ankylosing spondylitis and psoriatic 
arthritis.  
 
1.1 RHEUMATOID ARTHRITIS 
1.1.1 Clinical picture and epidemiology 
RA is a chronic inflammatory disease characterized by symmetric small joint 
polyarthritis. The prevalence of RA is approximately 0.5-1% in Western populations 
and the incidence rate varies between 20-50 cases/100,000 person- years depending 
on age and sex. [2-3] The usual age of onset is 40-70 years of age and the condition is 
2-3 times more common in women. RA typically presents with an insidious onset of 
symmetric swelling and pain in the small joints of the hands and feet, morning 
stiffness and fatigue. With time, the local joint inflammation leads to joint destruction 
with subsequent functional disability and decreased quality of life. Beside the local 
inflammation, systemic features such as extra-articular organ manifestations may 
occur. Patients with RA also have a decreased life expectancy mainly due 
cardiovascular events but also due to other co-morbidities such as malignant 
lymphomas.[4-5]  
 
1.1.2 Classification criteria 
As no single diagnostic test exists, the diagnosis of RA is often based upon 
classification criteria. The criteria set in widespread international use and also applied 
in all the studies of this thesis is the American College of Rheumatology (ACR) criteria 
from 1987 (Table 1).[6] Initially created for research purposes, the ACR criteria have 
been a useful tool in defining patients with established RA but are more limited in 
recognizing patients at an early stage of the disease. Thus, updated criteria were 
issued by the ACR and the European League Against Rheumatism (EULAR) in 2010. 
These consist of a score-based algorithm where a collective score from four categories 
are added.[7] The 2010 criteria (Table 2) focus on features at earlier stages of RA 
rather than defining established disease and also allow for the distinction of RA into 
two rather specific subsets, anti-citrullinated protein antibodies (ACPA) positive and 
ACPA negative RA (see section 1.1.3). 
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Table 1 - The ACR classification criteria for RA (1987) 
 
Criterion 
1. Morning stiffness 
2. Arthritis of ≥3 joint areas 
3. Arthritis of hand joints 
4. Symmetric arthritis 
5. Rheumatoid nodules 
6. Rheumatoid factor 
7. Radiographic changes 
Patients fulfilling at least 4/7 criteria are classified as having RA. Criteria 1-4 must be present 
for at least 6 weeks.  
 
 
Table 2 - The ACR/EULAR scoring criteria for classification of RA (2010) 
 
A. Joint involvement Score  
1 large joint 0 
2-10 large joints 1 
1-3 small joints  2 
4-10 small joints (with or without involvement of large joints) 3 
>10 joints (at least 1 small joint) 5 
B. Serology (at least 1 test result is needed for classification) Score 
Negative RF and negative ACPA 0 
Low-positive RF or low-positive ACPA 2 
High-positive RF or high-positive ACPA 3 
C. Acute-phase reactants (at least 1 test result is needed for classification) Score 
Normal C-reactive protein (CRP) and normal erythrocyte sedimentation 
rate (ESR) 
0 
Abnormal CRP or abnormal ESR 1 
D. Duration of symptoms  Score 
<6 weeks                        0 
≥6 weeks 1 
 
Target population, Patients who 1) have at least 1 joint with definite clinical synovitis 
(swelling) 2) with the synovitis not better explained by another disease. To be classified 
as rheumatoid arthritis, an overall score of ≥ 6/10 is required. 
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1.1.3 Etiology  
RA is considered a complex disease where genetic and environmental factors interact 
with the immune system causing the pathological changes. A family history of RA is 
associated with an approximately 3-fold increased risk of RA and there is a high 
concordance of RA between both monozygotic and dizygotic twins further supporting 
an impact of genetic effects. The strongest genetic risk alleles associated with RA are 
located in the human leukocyte antigen (HLA) class II region, in particular the HLA- 
DRB1 locus sharing a defined amino acid sequence, the so called shared epitope 
(SE).[8] Apart from this, several other susceptibility genes of interest are also 
identified.[9] However, although HLA-DRB1 SE has been suggested to account for a 
considerably part of the genetic influence in RA, especially in the ACPA positive subset 
of RA patients, the majority of the hereditability in RA remains unclear.  
 
Among environmental risk factors, smoking is by far the most established, with an 
approximate doubling of the RA risk.[10-14] High intensity and longer duration of 
smoking further increase the risk.[15] Recent studies have also shown an intriguing 
gene-environmental interaction where smoking and presence of the HLA DRB1-SE risk 
allele synergistically increase the risk of ACPA.[16]  This strengthens the idea of, at 
least, two distinct subsets of RA (ACPA positive and ACPA negative disease) with 
mutually different risk factors, clinical course as well as presumably also different 
molecular pathogenesis.[17] Based on the presence of autoantibodies, RA is 
traditionally considered an autoimmune disorder. Rheumatoid factor (RF) is present in 
about 80% of all patients and is associated with a more severe disease course as well 
as with joint destruction. RF is also shown to precede the onset of the clinical 
symptoms by many years.[18-20] In recent years, a lot of research has focused on the 
ACPA.  ACPA has a higher specificity for RA than RF and is present in about 60% of the 
patients at disease onset. As with RF, it is associated with a more severe disease and 
may be present several years before clinical RA onset.[18, 21]  This, together with 
recent data from animal and molecular studies and the observed gene-environmental 
interaction between smoking, SE and ACPA, indirectly support a possible causative 
role of ACPA in the RA pathogenesis.[17]   
 
Hormonal factors also play a role in RA development as illustrated by the gender 
distribution. For women, RA onset is common at times when sex hormones are 
fluctuating, such as in the postpartum period and after menopause. [2, 22] Several 
reports also support a protective effect of oral contraceptives.[22]  
Other environmental factors more or less consistently related to risk of RA include 
alcohol, infections, peridontitis, obesity and dietary factors.[22] 
 
1.1.4 Some aspects of RA pathogenesis  
Rheumatoid arthritis is characterized by inflammation of the synovial membrane 
surrounding the joint. In the synovium, numerous cells of the innate immune system 
are present and active, including macrophages, dendritic cells and leukocytes. The 
progression of inflammation (and the subsequent joint damage) is further facilitated 
by different pathways of the innate immune system and an interaction with adaptive 
immunity.[23-24] T cells have long been recognized as important players in RA 
pathogenesis. This is based on several factors, including the pronounced infiltration  
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of T cells in the synovium, the strong association to HLA class II (HLA being a key 
molecule responsible for antigen presentation to T cells) and the involvement of T 
cells in the production of tumor necrosis factor (TNF) and other pro-inflammatory 
cytokines. However, B cells also play multiple roles in the RA disease process in 
addition to producing autoantibodies.[25] B cells act as an antigen-presenting cell and 
produce pro-inflammatory cytokines.[9] Data also support that B cells are necessary 
for the activation of T cells in the synovial tissue.[26] The pivotal role of B cells is 
further supported by the fact that depletion of (CD20+) B cells is an efficient therapy in 
RA.[27] 
 
An important concept in the RA pathogenesis is the mechanisms and the production 
of pro-inflammatory cytokines[28] such as TNF, interleukin (IL)-6 and IL-1. These 
cytokines activate leukocytes, synovial fibroblasts and endothelial cells. When 
released into the circulation, they also mediate acute-phase responses that are 
responsible for the systemic features seen in the RA clinic, such as fatigue, loss of 
appetite and fever as well as laboratory measurements of acute-phase reactions, 
anemia and thrombocytosis. Tumor necrosis factor further induces the production of 
other cytokines and suppresses regulatory T-cell functions. Interleukin-6 promotes B- 
cell proliferation and thereby the production of antibodies.[9] The crucial roles of TNF 
and IL-6 is further confirmed by the successful RA therapies acting by blocking these 
particular cytokines.  
 
1.1.5 Disease activity  
There is no single test available to assess disease activity or level of inflammatory 
activity in RA. Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are 
commonly used, although neither of these is without limitations. For example, not all 
RA patients have elevated levels of ESR and CRP despite active disease.[29] ESR can be 
affected by RF and/or immunoglobulin thereby being a marker of disease severity 
rather than of inflammation[30]. The acute phase protein CRP may presumably 
function better as a measure of acute inflammation. Measurements of both ESR and 
CRP concomitantly probably fulfill the clinical needs in most situations.  
 
The most widespread measure of disease activity (originally developed to describe 
treatment results in clinical trials) is the 28-joint disease activity score (DAS28).[31] 
This is a composite index consisting of swollen (0-28) and tender joint counts (0-28), 
ESR, and the patient’s general health assessment on a visual analogue scale (0-100). 
DAS28 <2.6 is classified as disease remission, DAS28< 3.2 as low active disease, DAS28 
3.2-5.1 as moderate active and DAS28 >5.1 as high active disease.[35] In recent years 
DAS28 has become increasingly used also to evaluate patients at onset and during 
follow up in the clinical setting. Although the DAS28 score is a useful tool for the 
clinical evaluation, there are limitations. An overestimation of disease activity may 
occur if ESR is high (for other medical reasons) or if the patient scores high on the 
visual analogue scale due to non-RA related causes. Conversely, DAS28 does not 
include joint counts of the feet, which may underestimate disease activity. A recent 
study also observed a considerable discrepancy between DAS28 and the physicians’ 
assessment of disease activity.[32] Taking these considerations into account, an 
optimal clinical evaluation should probably include both DAS28 and the clinicians’ 
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global assessment. Other measures of disease activity not included in the studies in 
this thesis are different radiographic scores of joint damage and measures of physical 
function such as the patient-reported Stanford Health Assessment Questionnaire 
(HAQ).[33]  
 
1.1.6 Management and treatment  
There have been major improvements in the management and treatment of RA in the 
last 10-15 years. Today it is well-established that an early start with disease modifying 
anti-rheumatic drugs (DMARDs) is crucial in order to prevent joint damage and future 
disability. The importance of aiming for disease remission or low active disease is well-
recognized, although the acceptable level of residual disease activity and the optimal 
time span for reaching remission remain unclear.[23]  The mainstay of initial therapy is 
methotrexate (MTX), although other DMARDs such as sulfasalazine and leflunomide 
may be alternatives. If there is a sustained disease activity after 3 months of 
monotherapy, a combination of therapies should be used. This could imply MTX in 
combination with one or two other DMARDs or MTX in combination with tumor 
necrosis factor inhibitor (TNFi). The latter is recommended in the subset of RA 
patients with poor prognostic factors such as RF and/or ACPA positive disease, early 
radiographic changes or high disease activity. Apart from TNFi, several other 
biological agents have more recently been approved and are increasingly used in the 
treatment of RA ([34-35] serve as general references for this section). The issue of 
whether oral glucocorticoids should be a part of the initial standard therapy is 
debated. Data on the beneficial effects with respect to reduced radiographic 
damage is indeed convincing [36], but there are remaining concerns about potential 
long-term adverse effects.[37] 
 
It should also be noted that despite the fact that these therapeutic agents have been 
around for quite a long time, changes in treatment regimen have been gradual. As late 
as in the mid- to late 90’s, therapy guidelines still recommended rheumatologists to 
initially treat newly diagnosed RA patients with non-steroidal anti-inflammatory drugs 
(NSAIDs) and physical therapy and if DMARD’s were indicated, to primarily choose 
milder agents (such as antimalarial agents) and to use low doses.[38] Consequently 
patients diagnosed before 2000 (and sometimes even later on) have not benefited 
from the current treatment recommendations which may affect the disease outcome 
of these patients in the long term.  
 
1.2 SPONDYLARTHRITIS 
Spondylarthritis (SpA) is a heterogeneous group of disorders and can be regarded as a 
family with interrelated features rather than a single disease with different clinical 
manifestations. The disorders that make up this group include ankylosing spondylitis 
(AS), psoriatic arthritis (PsA), reactive arthritis (ReA), inflammatory bowel disease 
related arthritis (IBD-SpA) and undifferentiated spondylarthritis (uSpA). Data on 
prevalence for the entire SpA-group are limited but is estimated to be about 1-2%.[39] 
Although there has been a significant increased knowledge on how to classify,[40-41]   
and how to diagnose and treat patients of the SpA group in recent years, data on 
underlying etiology, disease course and co-morbidities remain much more limited 
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than for RA. For the purpose of this thesis, two of the SpA disorders, AS and PsA are 
described in some more detail. 
 
1.3 ANKYLOSING SPONDYLITIS 
1.3.1 Clinical picture and epidemiology  
AS is the best-defined disorder of the SpA group and is characterized by chronic 
inflammation of the sacroiliac joints and spine causing the characteristic inflammatory 
back pain. Clinical features further include enthesitis, peripheral arthritis (often 
asymmetrical and of the lower limbs) as well as extra-articular manifestations 
involving the eyes and sometimes the heart. The inflammatory activity and the 
structural damage of the spine lead to spinal stiffness and loss of mobility with 
subsequent functional disability. The prevalence of AS varies considerably with 
geographic area, estimates range from 0.3 to 0.5% in European populations.[42] There 
is a strong correlation between the prevalence of AS and the background population 
frequency of HLA-B27. In Northern Europe the estimated incidence is about 6 
cases/100,000 person-years.[43] The usual age of onset is 20-30 years of age and AS is 
twice as common in men.[44] With respect to co-morbidities, data support an 
increased risk of cardiovascular events[45-46]. To date, there has been no report of 
excess risk of cancer overall [47] with the exception of AS patients treated with 
radiotherapy in whom increased rates of leukemia have been observed.[48] 
 
1.3.2 Classification criteria 
The modified New York criteria are the most widely used set of AS criteria since their 
creation in the 1980’s (Table 3)[49]. These criteria require the presence of 
radiographic sacroiliitis, a feature often occurring rather late in the disease course. In 
recent years magnetic resonance imaging (MRI) has evolved as a useful diagnostic tool 
and enables identification of AS patients at an earlier stage of the disease. This, 
together with the breakthrough of TNFi therapy in this patient population, have 
strengthened the need for criteria identifying AS patients earlier after onset, and to 
distinguish those patients for whom biological treatment is indicated. Recently the 
Assessments of SpondyloArthritis International Society (ASAS) have developed 
classification and diagnostic criteria for axial spondylarthritis in order to meet this 
need.[50]  
 
 Table 3 - The modified New York criteria for ankylosing spondylitis (1984)  
 
 
 
 
 
 
 
 
Definite AS if the radiological criterion is associated with at least one clinical criterion 
 
Clinical criteria 
●Low back pain and stiffness for more than 3 months that improves with exercise, but   
is not relieved by rest. 
●Limitation of motion of the lumbar spine in the sagittal and frontal planes. 
●Limitation of chest expansion relative to normal values correlated for age and sex. 
Radiological criterion 
●Sacroiliitis grade ⩾2 bilaterally or grade 3–4 unilaterally. 
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1.3.3 Etiology and pathogenesis 
The etiology of AS is unclear, although there is a strong genetic effect i.e. the link to 
HLA-B27.[51] Data also suggest a role of HLA-B27 in the pathogenesis of AS and in 
other SpA entities.[39] The strongest evidence of this pathogenic role comes from 
experimental studies showing that over-expression of HLA-B27 in transgenic rats 
resulted in gastrointestinal and joint inflammations.[52] Although HLA-B27 is present 
in approximately 90% of the AS patients [51] it does not explain all genetic 
susceptibility in AS, suggesting the contribution of other genes.[39] With respect to 
environmental factors, a possible interaction between different infectious agents and 
HLA-B27 has been proposed. However, apart from the fact that patients with ReA 
(usually triggered by bacterial agents) rarely develop AS,[53] there is no clear evidence 
for any specific infectious agent in the etiology of AS. Smoking has been suggested to 
worsen the disease course.[54] As in RA, the activation of the pathways of the innate 
and adaptive immune systems lead to activation and production of pro-inflammatory 
cytokines where so far TNF seems to play a crucial role.[39] 
 
1.3.4 Management and treatment 
The mainstay of therapy for AS has traditionally consisted of NSAIDs in combination 
with physical therapy. Although NSAIDs remain the first line of pharmacological 
therapy, the introduction of TNFi has radically improved the treatment possibilities. 
This is particularly evident for AS patients with isolated spinal disease in whom 
DMARDs [55-56] have failed in controlling symptoms and disease progression 
(although sulfasalazine may improve peripheral joint manifestations).[56] The 
evidence for the efficiency of oral glucocorticoids in AS quite limited.[42] Recently the 
ASAS international working group published recommendations for the management 
of patients with AS[57] including guidelines for treatment with TNFi.[58] The 
guidelines conclude that TNFi should be considered in patients with persistently high 
disease activity despite treatment trials with ≥2 NSAIDs, and do not recommend the 
use of DMARDs before or concomitant with TNFi in patients with spinal disease. 
 
The most commonly used measure of disease activity in AS is the Bath Ankylosing 
Disease Activity Index (BASDAI)[50], which is increasingly used in the clinical setting. 
This includes six patient-oriented questions based on fatique, overall back and hip 
pain, peripheral arthritis, enthesitis and duration and intensity of morning stiffness.  
With regard to laboratory measures, data have shown a poorer correlation between 
disease activity and levels of CRP and/or ESR in AS than in RA.[59]   
 
1.4 PSORIATIC ARTHRITIS 
1.4.1 Clinical picture and epidemiology 
PsA is an inflammatory (usually sero-negative) arthritis associated with psoriasis. The 
typical presentation is an insidious onset of asymmetric oligoarthritis often including 
the small joints of hands and/or feet. Other clinical features are enthesitis, 
tenosynovitis, dactylitis (sausage digit), spinal disease and, as in AS, extra-articular 
manifestations. PsA occurs in approximately 30% of the patients with psoriasis,[42] 
corresponding to a prevalence of about 0.2% in Western populations.[60] The annual 
 8 
 
incidence is estimated to be 5-7 cases/100.000 person-years.[2, 60-61] The usual age 
of onset is 40-60 years and PsA is equally common in men and women.  
 
PsA was long considered a milder disease than RA. However, recent data have 
demonstrated disease progression over time, with associated joint damage and 
functional impairment resulting in a reduced quality of life similar to that of RA.[62] A 
decreased life expectancy has been reported primarily due to cardiovascular 
events.[46] Data on cancer risk in PsA are limited but do not signal any increased risks 
overall.[63] 
 
1.4.2 Classification criteria 
In the 1970’s, Wright and Moll described five different subsets of PsA. These subsets 
included predominantly distal joint disease, arthritis mutilans (a very destructive 
form), assymetric oligoarthritis (the majority of the patients), polyarthritis (inseparable 
from RA) and predominantly spinal disease.[64] This division into subsets got a 
widespread recognition although current data indicate that the majority of the 
patients with established PsA actually display a polyarthritis.[65-66] The  original 
classification has been followed by several different sets of criteria with rather large 
variations in the definition of PsA.[67] This has made results from both 
epidemiological and interventional studies difficult to compare over time.  
 
The latest set of criteria issued is the ClASsification criteria for Psoriatic ARthritis 
(CASPAR) aiming to distinguish PsA as a distinct entity. The CASPAR criteria are, 
however, thought to be used for research purposes rather than in a clinical setting. 
Subsequently the clinical diagnostic of PsA is still based on an overall assessment 
where several factors need to be taken into consideration, such as presence (or a 
family history) of psoriasis, type and distribution of joint manifestations, serological 
factors as well as presence of spinal disease. The diagnostic challenge is primarily to 
distinguish PsA from RA. For example, how to accurately diagnose a patient 
presenting with psoriasis, RF and polyarthritis. 
 
1.4.3 Etiology and pathogenesis  
Since psoriasis often precedes PsA, it has been hypothesized that some triggering 
events in the skin activate the innate and the adaptive immune responses resulting in 
the initiation of the disease process in genetically susceptible individuals. With respect 
to genetic factors, PsA is associated both with psoriasis-related genes (HLA- cw6) and 
also with genes prevalent in AS/SpA (HLA B-27), the latter predominately in PsA 
patients with spinal disease. Other genes have also been proposed to be of 
importance.[61] With respect to environmental factors, infection-related triggers as 
well physical traumas have been suggested. Data indicate that smoking may be a risk 
factor and also associated with a more severe disease and a worse prognosis, similar 
to the relationship between smoking and RA, although this is not as well explored as in 
RA.[54] There is also some suggestion of a link between obesity and risk of PsA.[68] 
An intriguing mechanism is the association between an increased occurrence of 
psoriasis and PsA in individuals with Human Immunodeficiency Virus (HIV) infection. 
Although this could imply a viral trigger for PsA, it could also be related to the 
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pathogenesis; HIV could change the balance between different types of T cells and 
lead to the development of PsA.[69]     
 
Evidence strongly supports the importance of T-cell immunity in PsA .The T-cells 
activation in turn leads to an activation of pro-inflammatory cytokines, in particular 
TNF [61]. This is also illustrated by the beneficial therapeutical effect seen with TNFi 
also in PsA. Other biological agents are in the pipeline, for example agents targeting 
interleukin 12/23 (already approved for psoriasis) and interleukin-17. This further 
emphasizes the importance of the cytokine cascade in the disease course of PsA.[68] 
 
1.4.4 Management and treatment 
Optimal treatment and management of PsA must focus on the different clinical 
manifestations of the disease and may include non-systemic as well as systemic 
treatments. MTX is the mainstay in the treatment of joint manifestations although 
data also support the use of sulfasalazine, cyclosporine and leflunomide. In the case of 
sustained disease activity despite DMARDs, treatment with TNFi (without continuation 
of previous DMARDs) should be considered. [42, 70] The definition of active disease is 
not as well characterized in PsA as in RA, but is in the current treatment guides for PSA 
defined as “evidence of active arthritis and/or at least moderate disease activity by 
some composite disease activity measure and/or active disease leading to impaired 
function”.[70] Traditionally the use of oral glucocorticoids in PsA has been restricted 
in PsA due to a fear of flares of psoriasis. Furthermore, data on efficacy is quite 
scarce. Despite this, oral glucocorticoids are commonly used in PsA.[70]  
 
With respect to assessments of disease activity in PsA, traditional measures used in 
RA (DAS scores) and in psoriasis (Psoriasis Area and Severity Index, PASI) have often 
been applied, however not without limitations. Although the DAS score is useful 
because it assesses the number of joints affected, the patient’s global assessment 
and includes laboratory measure such as CRP and ESR, it does not account for other 
manifestations of the PsA disease. Currently the Group for Research and Assessment 
of Psoriasis and Psoriatic Arthritis (GRAPPA) has suggested new composite measures 
on disease activity and on response to therapy with the aim to take different clinical 
features of PsA into account. However these new measures are not used in a clinical 
setting and not yet fully validated.[71]  
 
1.5 MALIGNANT LYMPHOMAS 
1.5.1 Classification 
Malignant lymphomas are a heterogeneous group of disorders deriving from 
lymphocytes in various stages of differentiation. Depending on the stage of the cell of 
origin, subtypes with different characteristics are formed. The heterogeneity of the 
group has made classification a challenge and several systems have been introduced 
over the years, which, for a long period, rested primarily upon morphological features.  
With the Revised European-American Lymphoma (REAL) classification issued in 1994 
[72], immunological, genetic and clinical characteristics were also taken into account. 
The REAL classification was further modified into the current, and today 
internationally accepted, World Health Organization (WHO) classification introduced 
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in 2001 [73] and updated in 2008.[74] The WHO system divides the lymphomas into 
more than 40 different subtypes based on morphology, genetics, immune phenotype 
and clinical features. For all subtypes a cell of origin is identified.  
 
Traditionally lymphomas have been divided into two main groups; non-Hodgkin 
lymphoma (NHL) accounting for about 90% of all cases and Hodgkin lymphoma (HL) 
making up for the remaining 10%. Non-Hodgkin lymphomas can further be divided 
into B-cell and T/NK- cell lymphoma, where the B-cell lymphoma accounts for the 
majority of the cases (>85%). The most frequent B-cell lymphoma types in Western 
populations are diffuse large B-cell lymphoma (DLBCL, 30-40%), follicular lymphoma 
(20-30%) and chronic lymphocytic leukemia (20-30%).[73, 75]   
 
For CLL, the staging system and prognostic factors differ in many aspects from that of 
other NHL. Thus, although CLL is recognized as a B-cell lymphoma according to the 
WHO classification, it is sometimes treated as a separate entity. For example many 
cancer registers (including the Swedish) apply the International Classification of 
Diseases (ICD) where CLL is included among other leukemias. Further, and of 
importance for this thesis, CLL is not rarely excluded from studies on the etiology and 
epidemiology of NHL which may have an impact on the interpretation and comparison 
of different study results. Plasma cell malignancies (plasmacytoma/myeloma) are also 
included among the NHL subtypes according to the most recent WHO classification 
but these entities are not under study in any of the papers of this thesis.  
 
Hodgkin lymphoma is characterized by typical neoplastic cells (Hodgkin and Reed-
Sternberg cells) that occur sparsely in the neoplasm. Although it is now known that 
these cells are primarily of B-cell origin, HL displays several morphological as well as 
clinical and epidemiological features that distinguishes this entity from other B-cell 
lymphomas. There are 2 main subtypes of HL, the nodular lymphocyte predominant 
HL (5%) and the classical HL (95%).[73]    
 
The diagnostic accuracy of lymphoma has varied over the years. The most relevant 
misclassification in Sweden is that of NHL as HL, where it is estimated that about one 
third of the diagnosed HL in the 70’s actually were NHL.[76-77] Despite major 
improvements through advances in genetics, technology and not the least in 
immunohistochemistry, diagnostics of lymphoma remains a challenge for the 
pathologist as well as for the clinician. 
 
1.5.2 Epidemiology 
In Sweden, malignant lymphomas account for approximately 4% of all cancer cases 
each year.[75] In 2011, about 2,500 new cases were diagnosed (NHL including 
CLL=2,323, HL=182) and the annual incidence rate in Sweden is estimated to be 29 
cases/100,000 person-years. Forty-five percent of the patients were women and the 
majority were older than 60 years of age at time of diagnosis.[75] Like most tumors, 
lymphoma becomes more frequent with increasing age, although the various 
subtypes show relatively different age profiles.[78] Since the 1950’s, there have been 
reports on increasing incidence rates of NHL from several countries including 
Sweden.[79] Periodically an annual percentage increase of about 3% has been 
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reported. With regard to subtypes, less information is available on time trends, but an 
increase has been reported for example for diffuse subtypes such as DLBCLs. Since the 
early 1990’s, the trend of increasing incidence of NHL has stabilized in several 
countries including Sweden. Still, the reason for this quite remarkable increase during 
the latter part of the 1900’s remains largely unclear [80-81] as only a smaller 
proportion can be explained by established risk factors and misclassification of 
diagnoses. Compared with NHL, the incidence rates of HL have been more stable over 
time.[82] 
 
1.5.3 Clinical aspects, treatment and prognosis 
Given the histological and molecular heterogeneity of malignant lymphomas there is a 
large variation in clinical presentation, clinical course, treatment and prognosis. A 
more in depth description is beyond the scope of this thesis, however, some brief 
aspects will be presented.  
 
Beyond the classification of subtypes according to the WHO system, the division of 
lymphomas into aggressive and indolent forms remains useful from a prognostic point 
of view. It also has implications for the choice of treatment. Aggressive lymphoma 
includes DLBCL, follicular lymphoma stage IIIb and peripheral T-cell lymphoma 
whereas CLL and follicular lymphoma (stage I, II and IIIa) are included in the indolent 
group. Another important factor for both treatment and prognosis is the localization 
(nodal or extranodal) and whether the disease is widespread. To distinguish localized 
(stage I and II) presentation from widespread disease, the Ann Arbor staging system 
(Table 4) is widely used for both NHL and HL (but not CLL).[83-84] Additionally, in the 
mid 1990’s the International Prognostic Index (IPI) was published. This scoring index 
separates patients into distinct groups with different prognosis based on five factors; 
Ann Arbor stage, level of serum lactate dehydrogenase, number of extra nodal sites 
involved, age, and performance status.[85] Originally IPI was developed on patients 
with DLBCLs, but a similar index has also been developed for HL[86]and for follicular 
lymphoma.[87] 
 
 
Table 4 - Ann Arbor staging classification of lymphoma, modified in Cotswold 1988. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stage Area of Involvement 
 
I Single lymph node group 
II ≥ 2 lymph node groups on same side of diaphragm 
II  ≥ 2 lymph node groups on both sides of diaphragm 
IV Disseminated extranodal involvement 
X Bulk > 10 cm 
E Extranodal extension or single, isolated site of extranodal disease 
A/B B symptoms: weight loss>10%, fever, night sweats 
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The advances in microarray technology have contributed with further prognostic 
information. For example, it is now recognized that DLBCL consists of two different 
subsets, initially distinguished through different gene expression profiling[88]; the 
germinal center (GC) type and the activated B cell-like (ABC) type (sometimes 
referred to as the non-GC type). Today, the two subsets can also be separated from 
one another by using immunohistochemistry technique.[89] The distinction between 
the GC and non-GC type is important from a prognostic point of view as the non-GC 
type has a poorer survival. 
 
The heterogeneity of lymphoma results in numerous treatment options and a widely 
accepted standard treatment exists only for a minority of the patients. For indolent 
lymphomas, it is sometimes sufficient to treat with a watch-and-wait policy whereas 
radiotherapy (often in combination with chemotherapy) is used in more aggressive 
disease. In recent years, biological agents, especially monoclonal antibodies against 
CD20 B cells,[90] have substantially contributed to an improved prognosis for patients 
with several different lymphoma subtypes and are increasingly used in the therapeutic 
arsenal alone or together with chemotherapy. A further treatment alternative in 
aggressive lymphomas consists of high dose chemotherapy followed by stem cell 
transplantation.[91]  
 
1.5.4 Some aspects of lymphoma pathogenesis 
As for cancer development in general, lymphomas constitute clonal expansions of 
normal cells, mainly B and T cells. The expansion arises through a multistep process of 
genetic aberrations that induces a selective growth of the malignant clone and finally 
the ability to outgrow surrounding cells and tissues.[92] With regard to the more 
common B-cell lymphomas, recurrent translocations that occur during the different 
steps of the B-cell differentiation are involved in the initial steps of the malignant 
transformation. These genetic lesions may in turn deregulate the lymphoid balance in 
several ways such as by; i) enhancing cell growth and proliferation, ii) blocking normal 
cell differentiation, and iii) preventing programmed cell death (apoptosis). However 
these initial translocations alone are not considered sufficient to cause lymphoma 
development, and further genetic alterations are needed for a complete malignant 
transformation.[93]  
 
The normal B-cell development includes several different stages and is initiated in 
the bone marrow with further differentiation in secondary lymphoid tissues such as 
lymph nodes. In some of these stages of differentiation, the B-cell genome is 
especially vulnerable for genetic aberrations.  For example, both the arrangement of 
the immunoglobulin genes of the pro-B cells in the bone marrow and disturbances 
during the response of mature B cells to antigen in the germinal center of the lymph 
nodes represent such vulnerable processes. Thus, DNA modifications at these stages 
might predispose to genetic abnormalities leading to lymphoma development. 
Furthermore, the subtype of lymphoma depends on where in the B-cell stage of 
differentiation the genetic aberration takes place.[93-94] The dysregulation of B cells 
may also occur through dysfunction of T-cell mediated immunosurveillance. As 
already stated in the section on pathogenesis in RA, T cells are of crucial importance 
in controlling B cells and therefore controlling the overall immune function. This can 
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be illustrated by the well defined link between risk of lymphoma following HIV/AIDS, 
a disorder characterized by imbalance between subsets of T cells.[95] 
 
Several biological mechanisms have been suggested to cause the genetic aberrations 
leading to lymphoma development. One example is oncogenic viruses, where a viral 
genome would interfere with normal cell growth in the lymphoid cell. Another 
mechanism is through direct carcinogenic factors that could lead to possibly genetic 
lesions. A third important biological mechanism (and of interest with respect to the 
subject of this thesis) could be chronic immune stimulation leading to an increased B-
cell proliferation which in turn could increase the risk of genetic aberrations. [96] 
 
1.5.5 Risk factors  
1.5.5.1 Genetic factors 
A family history of malignant lymphoma is associated with a 1.5 to 4-fold increased 
risk of NHL.[97-102] Even higher risks have been reported for HL [82, 98, 100, 103] and 
for CLL.[104] This familial aggregation of lymphoma indicates a role of genetic 
susceptibility in lymphoma development. Interestingly, some data points towards 
stronger association of lymphoma risk with siblings than with a parental history of 
hematopoietic malignancy.[98, 100] Moreover, there are indications that chemical 
and occupational exposures are associated with an even higher lymphoma risk in 
patients with a positive family history of cancer.[105-106] This may suggest the 
contribution of a shared environment in childhood and adolescence or a possible 
gene-environment interaction for the observed risk association.  
 
With regard to specific genes associated with lymphoma development in the general 
population, several genetic variants have been identified as potential susceptibility 
loci.[107] An interesting observation is the increased lymphoma risk associated with 
susceptibility alleles in pro-inflammatory (TNF and IL-6)[108-110] and regulatory  
(IL-10)[108] cytokines. Recent studies further observed an association between the 
HLA class II region and follicular lymphoma.[111-112] This highlights the importance 
of gene polymorphisms involved in immune function, inflammation, and antigen 
presentation for the lymphoma development. Other gene polymorphisms that are 
studied are genes involved in DNA repair/methylation, oxidative stress and hormone 
regulation.[107]  
 
However, so far the identified susceptibility variants indicate that common genetic 
variants with low penetrance influence lymphoma risk, presumably with further 
influence from gene-gene and gene-environment interactions. 
 
1.5.5.2 Inherited and acquired immunodeficiency 
Inherited and acquired states of immunodeficiency constitute strong and well-
established risk factors for lymphoma even though they altogether only explain a 
small part of all cases. With regard to inherited conditions, several rare 
syndromes/disorders are recognized, such as Wiskott-Aldrich syndrome, combined 
immunodeficiency and X-linked lymphoproliferative syndrome. The relative risk (RR) 
of developing lymphoma in these conditions is 10-200 times higher than expected 
and up to 25% of these individuals develop a lymphoma during their life-time.[73] 
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Although being extremely rare in the population, the inherited immunodeficiency 
syndromes are important for the understanding of lymphoma etiology overall.  
A defective immunosurveillance of Epstein-Barr virus (EBV) seems to be a primary 
mechanism behind lymphoma development in these conditions.[73] 
 
HIV/AIDS is associated with a highly increased lymphoma risk ranging from 15-400 
depending on lymphoma subtype and the population under study.[95] The most 
common subtypes reported are aggressive NHL including DLBCL and Burkitt 
lymphoma. Although there are reports of a decreasing trend in HIV/AIDS associated 
lymphomas with the introduction of antiretroviral therapy,[113-114] malignant 
lymphomas are still an important cause of mortality in this patient population.[95]  
Chronic antigenic stimulation resulting in immune dysregulation, genetic aberrations 
and loss of T-cell immunity against pathogenic viruses such as EBV and Human 
herpes virus 8 (HHV8) are suggested mechanisms behind HIV/AIDS related 
lymphomas. Overall, about 50% of all cases are estimated to be EBV-driven.[115]  
 
Long-standing immunosuppressive therapy following organ and bone marrow 
transplantation has also consistently been associated with risk of malignant 
lymphoma. The post-transplant lymphoproliferative disorder (PTLD) is a 
heterogeneous group consisting of different lymphoid proliferations ranging from 
benign hyperplasia to invasive malignant lymphoma. The majority of lymphomas are 
of B-cell origin.[116-117] The reported risks of developing PTLD are higher following 
heart transplantation compared to kidney transplantation.[118-119] A potential 
explanation is that more intense immunosuppression used in recipients of thoracic 
organs compared with in renal transplanted patients. The pathogenesis of PTLD is 
complex, but an interaction between chronic antigenic stimulation induced by the 
graft and impaired T cell immunosurveillance due to significant immunosuppression 
are suggested mechanisms.  The majority of the patients with PTLD have further EBV-
driven positive lymphomas indicating a dysfunctional immune response to a new or 
re-activated EBV infection.[117] However, not all EBV positive organ transplanted 
patients develop PTLD, indicating some additional unidentified stimuli other than 
EBV. Although such factors are not clearly identified, the chronic stimulation of B 
cells as well as the local cytokine environment may play a role.[116] Clinical 
characteristics shared by the majority of the immunodeficiency-related lymphomas 
are an association with EBV, B-cell origin, extranodal localized lymphomas and an 
aggressive clinical course.[73, 95, 115-116] 
 
1.5.5.3 Infectious agents 
Epstein-Barr virus (EBV) 
Epstein-Barr virus is a herpes virus with lymphocyte-transforming potential. It is 
usually acquired in childhood or early adolescence and about 90% of the worlds’ 
population is estimated to be EBV carriers.[116] After primary infection, the virus 
often persists lifelong in carriers as a latent asymptomatic infection of the B cells. In 
healthy infected individuals, malignant transformation of EBV-infected B cells is 
prevented by the presence of an intact T cell-mediated immunity. Thus, in states of 
severe immunodeficiency this control system may be impaired, leading to 
uncontrolled B-cell proliferation and sometimes to lymphoma development.[120] 
On the contrary, EBV infection is also present in lymphomas in immunocompetent 
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individuals such as (African) Burkitt lymphoma, as well as in some rare T/NK-cell 
lymphoma.[121] Hodgkin lymphoma is also associated with EBV infection, especially 
classical HL where EBV is identified in the tumor cells in approximately 40% of 
cases.[122]  
 
Other infections agents 
Two other lymphocyte-transforming viruses also display an association with 
lymphoma. The human herpes virus 8 (HHV8) is the causative agent of Kaposi’s 
sarcoma but is also associated with primary effusion lymphoma, a rare subset of 
NHL primarily affecting individuals with HIV/AIDS. Co-infection with EBV is common. 
The human T lymphotropic virus type I (HTLV-I), a retrovirus, is an established cause 
of adult T-cell leukemia/lymphoma.[73, 121]   
 
Hepatitis C (HCV) has in several (but not all) studies been associated with an 
increased risk of NHL by 2- to 10-fold.[123-124] There are substantial differences 
across studies possibly reflecting both geographically different study populations as 
well as methodological differences across the studies. The highest risks are reported 
from geographical areas with high prevalence of HCV in the population. Suggested 
mechanisms are chronic antigen stimulation leading to B-cell proliferation and to 
lymphoma development. Other infections suggested to be associated with specific 
subtypes of lymphoma are; Helicobacter pylori and gastric Mucosa-associated 
lymphoid tissue (MALT) lymphoma, Campylobacter jejuni and small intestine 
NHL.[121] 
 
1.5.5.4 Environmental factors 
Lifestyle factors  
Studies on smoking and risk of lymphoma have been conflicting.[125] A recent pooled 
analysis of 9 case-control studies from the International Lymphoma Epidemiology 
Consortium (InterLymph), noted no increased risk of NHL overall, but a significant 
increased risk confined to follicular lymphoma.[126]  A similar observation was noted 
in a large Swedish-Danish case-control study, although the increased risk noted for 
follicular lymphoma was restricted to women.[127] Hodgkin lymphoma has also been 
associated with increased lymphoma risk although excess risk among smokers has 
been quite modest. [127-128] For alcohol the association is weak and if anything data 
indicate a slightly reduced lymphoma risk associated with alcohol consumption.[129-
131] With respect to obesity, several studies have observed a positive association, 
whereas others have not.[132-133] The strongest association reported is of severe 
obesity and risk of DLBCL.[133] Further, high protein and high fat intake has been 
associated with a small increased risk of NHL, whereas high vegetable and fruit intake 
has been reported to reduce the same risk.[134-135] Although the observations with 
respect to obesity and dietary factors do not explain significant proportion of the 
lymphoma cases, it may be of interest from an etiological perspective. Obesity may, 
for example, promote a state of low grade, chronic inflammation and increased 
production of pro-inflammatory cytokines that in turn deregulate T-cell immunity 
and promote B-cell proliferation.[132]  
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Other environmental factors 
The link between ultraviolet radiation and risk of NHL has been debated. Initially it 
was hypothesized that sun exposure might be associated with an increased risk given 
the elevated risk of lymphoma following a diagnosis of skin cancer (implicated that 
sun exposure could be a common risk factor for both conditions). However, recent 
data point to a lymphoma protective effect of sun exposure in particular recreational 
ultraviolet radiation.[136-137] Potential biological explanations behind this remain 
unclear, although vitamin D pathways have been proposed as possible mechanisms. 
Exposure to moderate to high ionising radiation has consistently been associated with 
increased risk of leukemia especially for individuals exposed in childhood.[138] 
A corresponding risk for lymphoma has not been shown.[139-141]  
Several studies have suggested an association between occupational exposure to 
solvents such as benzene, toluene and xylene, whereas the associations between 
specific chemicals and/or specific lymphoma subtypes have been inconclusive.[142-
144] Another suggested exposure is pesticides. However, a recent published European 
pooled analysis provided limited evidence for an increased risk of specific lymphoma 
associated with exposure to pesticides.[145] 
 
1.6 CHRONIC INFLAMMATION AND RISK OF LYMPHOMA 
A clear association with lymphoma has consistently been demonstrated for certain, 
autoimmune/chronic inflammatory conditions and constitutes one of the best-
established lymphoma risk factors (apart from severe states of immunodeficiency).  
Increased risks are today well-established in patients with Sjögren’s syndrome (SS), 
systemic lupus erythematosus (SLE) and RA. [146-147]Also celiac disease, dermatitis 
herpetiformis and chronic thyroiditis[148] have repeatedly been associated with 
lymphoma development. In other diseases, such as inflammatory bowel syndrome, 
psoriasis, systemic sclerosis[148-151], granulomatosis with polyangiitis (formerly 
Wegeners granulomatosis),[152-153] sarcoidosis [154-156], and ankylosing 
spondylitis, data on lymphoma risk are more conflicting, or as for psoriatic arthritis 
poorly studied. The distribution and the magnitude of increased lymphoma risk varies 
markedly amongst different studies. In general, earlier and smaller studies of selected 
(often hospitalized-based) patients have reported higher risks compared with more 
recent, larger population-based investigations. One explanation for this could be that 
population-based studies include patients with milder disease.The majority of studies 
have addressed risks of NHL, but there are evidence of increased risks of HL especially 
in RA and SLE. Furthermore, evidence is accumulating that the inflammatory 
response caused by chronic inflammatory conditions may result in a higher risk for 
specific lymphoma subtypes and to lymphoma development in the target organ of 
the disease in question such as in SS, celiac disease and thyroiditis[147] 
 
In SS the risk ratios reported range from 2-48[155, 157-161] with an average RR of 
about 19.[162] Higher risks are generally reported for primary SS than for SS 
secondary to other autoimmune disorders.[163] There is a strong association 
specifically with mucosa-associated lymphoid tissue (MALT) lymphoma, which is 
localized in the target organ, the salivary glands,[73] but increased risks of DLBCL[164] 
are also observed. In a recent large pooled analysis of case-control studies within the 
InterLymph consortium, there was a 9-fold increased risk of DLBCL and a 30-fold 
increased risk of MALT lymphoma.[165] Several clinical characteristics at the time of 
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the SS diagnosis have been shown to be correlated with future lymphoma 
development including low C4 complement level, palpable purpura, cryoglobulinemia, 
splenomegaly, and lymphopenia.[155, 158, 166-167] This indirectly suggests that 
disease severity and/or disease activity may be of importance for the underlying 
lymphoma risk in SS.  
 
For SLE, lymphoma risk is overall about 3-6 times higher than in the general 
population, although some studies have reported even higher risks.[154, 156, 168-
175] In the meta-analysis from Zintzaras et al., the pooled SIR was 7.4.[162] Studies 
have shown that SLE patients have a 3 to 5-fold increased risk for HL also.[171-172, 
176] With regard to risk determinants, data indicate that hematological SLE 
aberrations, sicca symptoms, and pulmonary involvement [177-178] are associated 
with future risk for lymphoma development. There are also indications of a potential 
link between high SLE damage score and lymphoma risk[179] whereas immuno-
modulatory treatment was unrelated to risk in these studies.[177-179] Additionally 
the study of Bernatsky et al. [179] noted that the greatest risk of cancer existed 
earliest in the course of SLE which may suggest that cancer risk is not entirely 
explained by cumulative exposure to immune-modulatory treatment. Conversely, a 
very recent case-cohort study of 75 SLE-lymphomas and 4,961 cancer-free SLE 
controls found higher lymphoma risks with exposure to cyclophosphamide and high 
cumulative glucocortiocoids, but not with disease activity itself.[180] This illustrates 
the difficulties with disentangling the effect of a treatment from that of the 
underlying condition. With regard to NHL subtypes the most commonly occurring 
form in SLE is DLBCL [154, 165] and in the study of Löfström et al.[178] the majority of 
these (80%) were the prognostic less favorable non-GC type. 
 
Celiac disease (mainly located in the small intestine) and dermatitis herpetiformis 
(affecting the skin) are related conditions associated with gluten intolerance. In a 
recent meta-analysis, Tio et al. observed a pooled RR of about of 2.6 for NHL and an 
RR of almost 16 for T-cell lymphoma in patients with celiac disease.[181] Furthermore, 
there is a strong association with the rare enteropathy-associated T-cell lymphoma of 
the small intestine in patients with celiac disease [73]  and also evidence for increased 
risks of B-cell lymphoma.[154, 182-183] Dermatitis herpetiformis is also associated 
with an increased risk of lymphoma.[184] Interestingly, some studies have indicated, 
although not conclusively, that a gluten-free diet may be protective of lymphoma in 
both conditions.[184-185] 
 
A problematic issue when studying the link between inflammatory conditions and 
lymphoma risk is that autoimmune rheumatic features may occur in the course of the 
lymphoproliferative malignancy, sometimes being the first sign of a cancer. These so-
called paraneoplastic autoimmune phenomena may lead to misclassification of the 
undiagnosed lymphoma as an autoimmune disorder. For some inflammatory 
conditions this issue has turned out to be particularly relevant such as in 
inflammatory myositis and autoimmune haemolytic anemia. In both of these 
conditions, increased lymphoma risks have been reported but the lymphomas have 
typically occurred around the time of the diagnosis of the inflammatory 
condition.[156, 186]  
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1.7 RHEUMATOID ARTHRITIS AND LYMPHOMA 
 In the 1970’s, Isomäki et al.[187] presented a study indicating that patients with RA 
had an increased risk of lymphoma of about 2.7. Since then, this observation has been 
replicated in several case-control and cohort studies, although with a few exceptions 
(Table 5). The reported RRs for lymphoma overall range from 1.5-4, with an average 
RR of about 2.[162, 188] In general, studies including patients hospitalized for RA have 
observed higher risks than studies of non-hospitalized patients or when the exposure 
of RA has been self-reported. Data also indicate higher risks in men than in women 
with RA.[189-191] Although most studies have not shown an excess in cancer deaths 
overall in RA,[5]  mortality due to lymphomas in RA appears to be approximately 
doubled compared with the general population.[5, 190] Despite increased knowledge 
on the link between RA and lymphoma in the last 10-15 years, the underlying 
mechanisms behind this association are not fully understood.[147, 192] Potential risk 
factors that have been investigated during the years include RA-disease related factors 
such as inflammatory activity, the immune-modulatory treatment used in RA, and 
shared genetic (and/or environmental) factors common for both conditions. 
 
1.7.1 Inflammatory activity  
Several factors indicate a clear correlation between inflammatory activity and/or 
disease severity in RA and risk of lymphoma. An early study by Gridley et al.[193] 
observed a notably higher lymphoma risk in men with Felty’s syndrome, a severe 
complication of long-standing RA. Higher risks seen in patients hospitalized for RA 
further support an RA-disease related effect, assuming that hospitalized RA patients 
constitute a group with a more severe disease.[194-195] A problematic issue over 
the years has been to distinguish effects of treatment from the effects of the RA 
disease, given the obvious potential for channeling bias. Smaller studies with 
detailed information on both treatment and disease activity have rarely had the 
power to address this issue and larger registry-based studies have often had limited 
access to detailed information on disease characteristics. In some studies, clinical 
features, indirectly or directly, associated with RA disease activity and/or severity 
have shown to correlate with lymphoma risk including secondary SS, high ESR, 
erosive joint history and level of HAQ [163, 189, 196]. However, the strongest 
evidence for an association between RA disease activity and lymphoma risk is 
provided by the case-control study by Baecklund et al.[197] including 378 RA 
patients with lymphomas and 378 RA patients without lymphoma, hospitalized for 
RA 1964-1994. In this study the RA patients were divided into high, medium and low 
accumulated disease activity during the entire RA course based on a scoring system 
including number of swollen and tender joints, ESR, and the doctor’s global 
assessment. The information was abstracted from the medical records and included 
detailed information on treatment. High active disease was associated with a 71–
fold increased risk of lymphoma compared with low active disease whereas 
moderate activity conferred an RR of almost 8. Conversely, treatment was not 
related to increased lymphoma risk.[197] However, it must be remembered that the 
results of this study do not reflect current RA treatment strategies (none of the 
patients in the study of Baecklund et al. had been treated with TNFi) and cannot 
easily be compared with RA patients diagnosed and treated today.  
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Studies assessing whether lymphoma risk increases with time since RA diagnosis 
have been inconclusive.[148, 198, 206-209] Most reports on this subject have 
included prevalent rather than incident RA patients making it impossible to assess 
lymphoma risk as a function of time since onset of RA.[148, 198, 208] In the studies 
where the patient population has consisted of incident RA or polyarthritis, the 
number of lymphoma cases has been insufficient to draw reliable conclusions due to 
low statistical power.[206-207] In one study there was a small, however non-
significant, trend suggesting a possible increasing lymphoma risk with long-standing 
inflammation.[209]   
 
1.7.2 Immune-modulatory treatment  
1.7.2.1 Disease modifying anti-rheumatic drugs (DMARD) 
With respect to DMARDs, MTX and azathioprine are the two agents most commonly 
associated with increased lymphoma risks.[73] Several case reports and case series 
have presented lymphomas in patients treated with MTX as well as reports that a 
considerably proportion of these lymphomas obtain spontaneous (sometimes 
complete) remission when treatment is withdrawn.[210-212] However larger 
population-based studies have failed to show any increased lymphoma risk 
associated with MTX overall[189, 197, 213-214] although there are exceptions.[206, 
215] In some studies, data were too limited to completely explore disease activity 
[189, 206, 213, 215]. Alternatively, disease activity has been accounted for through 
indirect measures such as DMARD polytherapy, use of oral glucocorticoids  and 
extra-articular manifestations.[214] Baecklund et al.[197] reported no increased risk 
with MTX and accounted for disease activity by using a measure of accumulated 
disease activity (area under the curve, AUC) during the entire RA disease course. 
Taken together, there is no strong evidence supporting that MTX per se would 
increase the risk of lymphoma. However, concerns about the impact of MTX in the 
lymphoma development of the so-called “methotrexate-associated lymphomas” 
remains.[73] Interestingly, these particular lymphomas often present with a clinical 
picture similar to those seen in immunodeficient patients including lymphomas of 
primarily B-cell origin, EBV identified in lymphoma tissue, and extranodal 
localization.[210-212] 
 
Azathioprine has repeatedly been associated with risk of lymphoma in the post-
transplant setting,[73] but also in the setting of RA and inflammatory bowel 
syndrome (IBD). For RA, older studies have been inconclusive; some have shown 
increased risk,[216] others have not,[217] again with the problematic issue of 
distinguishing treatment effects from the risk of the underlying condition. Two more 
recent studies have also noted that treatment with azathioprine was associated with 
an increased risk of lymphoma in RA [197] [214], this increase in risk remaining after 
adjustments for accumulated inflammatory activity in the Swedish study [197]. In 
the setting of IBD, increased risks following treatment with azathioprine have been 
presented in several studies.[218-220] Few of these have been able to account for 
disease severity of IBD. 
 
The carcinogenic effects of cyclophosphamide are well known and increased risks of 
cancer overall, urinary bladder cancer and acute myeloid leukemia have been 
reported in patients treated with this agent.[153] For RA patients, evaluations have 
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been difficult due to lack of power,[221-222] although there is no strong evidence of 
increased lymphoma development in RA patients due to cyclophosphamide. 
Furthermore, a recent study assessing cancer risk in association with exposure to 
cyclophosphamide in patients with Wegener’s granulomatosis, did not detect an 
excess risk of NHL, whereas risk of acute myeloid leukemia was significantly 
elevated.[153]  
 
With respect to other DMARDs there are, overall, no signals of increased lymphoma 
risk associated with sulfasalazine, antimalarial agents or cyclosporine, although data 
are limited. [197, 202]  
 
1.7.2.2 Glucocorticoids 
Glucocorticoids have been widely used against RA for more than 50 years, and 
recently have experienced somewhat of a revival, particularly in the treatment of early 
RA.[36,223] Despite their extensive use, a comprehensive understanding of their 
mechanisms of action in RA is still lacking.[224] Previous studies on treatment with 
glucocorticoids and risk of lymphoma have reported both increased [225-226] as well 
as non increased risks [159, 209, 227-228] (reviewed in a meta-analysis of Bernatsky et 
al.[229] ). Partly this discrepancy can be explained by various degrees of channeling 
bias due to the underlying conditions treated with glucocorticoids. In an RA context, 
data are more limited but also have mixed results.[159, 197, 209] Interestingly, a 
study by Smedby et al.[209], the increased risk of NHL with respect to glucocorticoids 
was restricted to patients treated due to underlying RA whereas this risk was not 
apparent in non-RA patients taking glucocorticoids for other indications. By contrast, 
the study by Baecklund et al.[197] noted a reduced lymphoma risk associated with 
oral glucocorticoids in RA patients. 
 
1.7.2.3 TNFi and lymphoma in rheumatoid arthritis  
Ever since the approval of TNFi, there have been concerns that the strong immune-
modulating effects of these agents may induce development of lymphoma (or other 
cancers). The potential mechanisms behind this are complex. TNF is a key cytokine in 
the inflammatory cascade and seems to be of importance for the T-cell mediated 
immunity. Blocking of the natural functions of TNF might therefore theoretically lead 
to an impaired T-cell response, decreased tumor surveillance and subsequently to a 
possible cancer/lymphoma development. On the other hand, the local inflammatory 
responses mediated by TNF (and other inflammatory mediators) are also suggested to 
be of importance in the etiology of certain cancer forms. From this perspective, TNFi 
may instead decrease cancer/lymphoma risk.[230]  Additionally, in an RA context, 
TNFi could potentially reduce lymphoma risk, given their efficiency in lowering 
inflammatory activity. The net sum of all these mechanisms is obviously complicated. 
   
Data evaluating lymphoma risk in association with TNFi exposure have been 
inconsistent. In the meta-analysis by Bongartz et al. in 2006 [231] including 3,493 TNFi 
exposed RA patients and 1,512 placebo treated RA patients indicated an increased 
occurrence of lymphoma during (and after) end of follow up of the trials, although 
lymphoma-specific relative risks were not presented. By contrast, two more recent 
meta-analyses on this subject did not detect any increased lymphoma risk above what 
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is expected in an RA population.[232-233] Leombruno et al.[232] found a pooled RR of 
lymphoma of 1.3 (95% CI 0.5 to 3.1) whereas the recent meta-analysis by Lopez-Olivo 
et al.[233] noted a pooled RR of 2.1 (95% CI 0.6-8.4).  
 
In observational studies, the association between lymphoma and exposure to TNFi has 
to some extent varied (Table 6). Although the majority of studies have not reported 
increased risks in TNFi exposed RA patients compared with patients treated with 
classical DMARDs, there are exceptions. Geborek et al.[234] observed a 5-fold 
increased lymphoma risk in TNFi exposed RA patients versus non-exposed patients, 
although risk estimates were imprecise. Pallavacini et al.[235] also noted a 
substantially higher standardized incidence ratio (SIR) of lymphoma than what would 
be expected in an RA population overall. Interestingly, in the study by Askling et 
al.[236] risks of lymphoma were higher in RA patients starting TNFi 1998-2001 versus 
patients starting 2002 or later. This may suggest that RA patients treated with TNFi in 
the beginning of the biological era had a more severe disease than RA patients started 
on TNFi more recently. Assessments of lymphoma subtypes in relation to TNFi 
exposure are limited and have so far been hampered by the small number of 
events.[237-238] Furthermore, there are signals of different lymphoma risks 
depending on the type of TNFi agent received. A recent French study noted higher 
risks in RA patients treated with the anti-TNF monoclonal antibodies; adalimumab 
and infliximab than for the TNF-soluble receptor, etanercept.[239] In the publication 
the authors discuss a potential higher efficacy of the anti-TNF monoclonal-
antibodies in inhibiting membrane TNF signalling leading to a decreased 
immunesurveillance as one possible explanation.  
 
With respect to other biological agents and risk of lymphoma, data are limited but 
there are no signals of increased risks so far.[233] One particularly interesting agent 
in this respect is CD20+ B-cell depleting therapy (rituximab). Rituximab is 
successfully used in therapy for certain lymphomas and also in the treatment of RA 
(and other inflammatory conditions). This shared treatment further underscores the 
close link between lymphoma and autoimmunity.[96]  
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Table 6 - Observational studies of lymphoma risk in patients with rheumatoid 
arthritis exposed to Tumor Necrosis Factor inhibitor (TNFi).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1Relative risk expressed as SIR= Standardized incidence ratio, with 95% Confidence interval (CI) 
2 Relative risk, with 95% CI 3Only including NHL, 4Including NHL, HL, CLL and myeloma  
5Compared with a general population comparator group 6Compared with data in Milan cancer 
report and Varese Cancer Registry database respectively.  NR= Not reported  
NHL = Non-Hodgkin lymphoma HL= Hodgkin lymphoma CLL= Chronic lymphocytic leukemia 
 
 
1.7.3 Shared genetic and/or environmental risk factors  
Some of the susceptibility genes implicated in lymphoma pathogenesis have also been 
proposed as risk genes for RA. [241-243] Hypothetically, it may thus be that the 
increased lymphoma occurrence in RA is not a cause-and-effect association, but a 
result of shared genetic factors common for both conditions. However, in studies 
evaluating the lymphoma occurrence in relatives of RA patients there are no 
indications of any increased lymphoma risks [148, 198, 244] suggesting that the 
contribution of shared genetic susceptibility is low. On the other hand, considering the 
complex genetics of both diseases, and the clustering of lymphomas in the subset of 
RA patients with the most severe disease [197], it cannot be excluded that shared 
genetic susceptibility exists but only in the presence of (high) inflammation and/or in 
addition to immune-modulatory treatment.   
 
 
Author  
Year [ref] 
Country Study period  Risk vs. general 
population 
comparators1 
(95% CI) 
Risk vs. TNFi-naïve 
RA patients2 
 
( 95% CI) 
Wolfe 
2004 [189] 
UK 1999-2002 2.9 (1.7-4.9) NR 
Askling  
2005 [207] 
Sweden 1999-2003 2.9 (1.3 to 5.5) 
 
1.1 (0.6-2.1) 
 
Geborek 
2005 [234] 
Sweden 1997-2002 12 (3.7-27) 
 
4.9 (0.9-26) 
Setoguchi 
2006 [240] 
US/ 
Canada 
1994-2004 2.2 (1.7–2.9)3 
 
1.1 (0.5-2.4)4 
Wolfe  
2007 [199] 
UK 1998-2006 1.8 (1.5-2.2) 1.0 (0.6-1.8) 
Askling  
2009 [236] 
Sweden 1998-2006 2.7 (1.8-4.1)5 1.4 (0.8-2.1) 
Mariette  
2010 [239] 
France 2004-2006 2.3 (1.6-3.3) NR 
Pallavicini 
2010 [235] 
Italy 1999-? NR 6.0 (1.6–15)6 
5.0 (1.3–13)6 
NR 
Carmona 
2011 [238] 
Spain 2001-2008 NHL 1.5 ( 0.3-4.4) 
HL 5.3 ( 0.1-29) 
NR 
Dreyer  
2012 [237] 
Denmark 2000-2008 NHL 1.9 (0.8-4.5) 
HL 8.3 (2.1-33) 
CLL  2.4 (0.8-7.5) 
NHL 0.6 (0.2-2.2) 
HL  - 
CLL  3.1 (0.3-31) 
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Few environmental risk factors shared by lymphoma and RA are recognized. Among 
infectious agents, EBV is involved in the lymphoma development especially in patients 
with states of immune-deficiency. There is also a link between EBV and some 
particular lymphoma subtypes that are commonly observed also in RA such as DLBCL 
and HL. On the contrary, studies do not indicate that presence of EBV in RA-
lymphomas is higher than in lymphomas in the general population. [197, 245] 
Smoking is identified as a risk factor for RA [10-14] and has also in some studies been 
associated with lymphoma development.[125] However, this association is not 
consistent and may not explain the excess risk of lymphoma in RA on a population 
level.  
 
1.7.3.1 Characteristics of lymphoma in RA 
With respect to specific subtypes of lymphoma in RA patients, the majority of studies 
have assessed risk of lymphoma overall or risk of NHL. Data indicate an even higher 
risk of HL, although with less precise risk estimates.[190-191, 198, 200, 202-203] Risk 
of CLL is not as well-investigated and has often been studied together with other 
leukemias in RA. When assessed separately there are no strong signals of increased 
risks.[154] Similar evaluations in SLE and SS, have neither reported any increased 
occurrence of CLL.[154-155, 246] 
 
For RA, DLBCL has so far shown the strongest association. In the study by Baeckund et 
al. the histopathological classification showed that almost 50% of the RA-lymphomas 
were of DLBCL-type. Further, these DLBCLs displayed a strong association with disease 
activity and clinically often presented with extranodal involvement and advanced 
stages of lymphoma disease.[197] A follow-up study based on the same patient 
population revealed that 70% of the DLBCLs consisted of the prognostic less 
favourable non-GC type.[247] In studies assessing lymphoma risk by subtype, two 
studies observed modestly increased risks of DLBCL in RA [154-155] whereas another 
study did not detect any specific increased risk.[204]  EBV-positive lymphomas seem 
to be less common in RA and in other inflammatory conditions than in lymphoma-
patients with states of immune-deficiency. In one study, including MTX- treated RA 
patients, 17% of the NHL (3/18) and 71% of the HL (5/7) where EBV-positive.[213] and 
in the study of Baecklund et al. only 12% of all the RA-lymphomas were EBV-
positive.[197] Similar results have been reported from studies assessing the presence 
of EBV-positive lymphomas in other inflammatory conditions. [178, 245] 
 
In summary, due to the dramatic change in treatment strategies for RA in recent 
years, aiming at disease remission and low inflammatory activity using new treatment 
regimens, one could hypothesize that the risk as well as the presentation and clinical 
course of lymphomas in RA patients may have changed. Data on this subject is limited. 
Little is known whether the distribution of lymphoma subtypes is different in RA 
patients diagnosed and treated today compared with the lymphoma distribution 
reported from historical RA cohorts, i.e. in RA patients with a presumably higher 
disease activity and higher inflammatory load over time.  
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1.8 SPONDYLARTHRITIS AND LYMPHOMA 
In contrast to RA, data on lymphoma risk in patients with spondylarthritis (SpA) are 
more limited, but indicate potential differences between different SpA entities.  
For AS, previous studies have not observed increased lymphoma risks overall [155-
156, 205, 248-249]  apart from one retrospective cohort study (published in abstract 
only) identifying an incidence rate ratio (IRR) of lymphoma of 2.8 among AS patients 
(Chibata et al. Eular 2004, OP0131). Corresponding data for PsA are scarce and to my 
knowledge consist of one study assessing cancer risks in PsA patients followed 
prospectively 1978-2004, reporting a SIR for all hematopoietic malignancies combined 
of 0.7 (95% CI 0.3–1.8).[63] By contrast, cutaneous psoriasis has repeatedly been 
linked to increased lymphoma risk,[155, 250-252]  in particular T-cell lymphoma,[155, 
165, 253] although other studies have failed to observe any excess risk at all.[172, 203, 
205] Furthermore, there is some evidence of a link to disease severity and/or to 
systemic treatment of psoriasis.[254-255] 
 
In IBD patients, available data support that the average risk of lymphoma is similar to 
or just slightly higher than that of the general population (reviewed in a recent meta-
analysis by Pedersen et al.[256]), although increased risk in a subset of patients 
treated with purin analogs such as azathioprine has consistently been reported.[218-
220] The meta-analysis of Kandiel et al. observed a SIR for lymphoma in IBD patients 
treated with azathioprine of about 4, based on 11 observed lymphomas versus 2.6 
expected and with a significant variability in the estimated SIR between the 
studies.[219] Again, whether this risk was due to the medication itself or to the 
underlying disease severity could not be fully elucidated. 
 
Recently there has been a particular concern regarding the rare, but aggressive 
hepatosplenic T-cell lymphoma (HTCL) in patients with IBD. Several cases of HTCL have 
been presented mainly in young male patients with Crohn’s disease, treated with a 
combination of TNFi and azathioprine.[257] The mechanisms behind this potential 
association between HTCL development and the combinations of these agents remain 
unclear.  
 
1.8.1.1 TNFi and lymphoma in spondylarthritis 
The lymphoma risk associated with TNFi in patients with IBD has been difficult to 
quantify as most patients are also treated with other immune-modulatory agents 
including azathioprine. One meta-analysis including 26 studies of different study 
designs noted an SIR of NHL of about 3.[258] However, the majority of the patients 
had concomitant or previous exposure to immune-modulatory agents and in a 
comparison between TNFi exposed patients versus patients treated with immune-
modulatory agents alone the RR was 1.7 and did not reach statistical significance. In 
another meta-analysis of 21 placebo-controlled clinical trials designed to evaluate 
the safety and efficacy of TNFi therapy for Crohn’s disease, there were no 
differences in the frequency of malignancies between the TNFi exposed and non-
exposed group.[259] However, and important to emphasize, clinical trials rarely 
have enough follow up time to study an outcome such as lymphoma. Nevertheless, 
in contrast to the more convincing evidence of lymphoma risks in association with 
purin analogs such as azathioprine in IBD patients, the evidence for an increased risk 
of TNFi per se seems less evident. 
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In contrast to IBD, patients with AS are often treated with TNFi in mono-therapy, 
especially AS patients with predominantly spinal disease. Because there is a seemingly 
non-elevated lymphoma risk in AS overall, this patient population is an ideal model for 
risk assessments of TNFi therapy. However, so far, data on lymphoma risk in AS and in 
PsA patients exposed to TNFi have been hampered by small numbers of events 
making risk estimation difficult. [237, 239, 260]  One study, evaluating long term 
safety of adalimumab, observed an SIR of lymphoma in AS patients of 1.9 and a SIR of 
almost 6 in PsA patients.[260] Since these estimates were based on 1 lymphoma 
among 1,684 AS patients and 2 lymphomas among 837 PsA patients, the risk 
estimates were instable. Another study noted an SIR of lymphoma for AS and PsA 
combined of 1.9 (0.9-4.0) based on 7 lymphomas in patients with AS or PsA.[239] 
Thus, there is a need for more stable risk assessments in these patient populations. 
 
1.9 MECHANISMS BEHIND CHRONIC INFLAMMMATION AND RISK OF LYMPHOMA 
Proposed mechanisms behind increased lymphoma development in patients with 
inflammatory conditions include accumulated inflammatory activity per se, chronic B-
cell stimulation, shared genetic susceptibility and/or environmental factors as well as 
a possible impact of the treatment.  
  
As discussed in the section 1.5.4, lymphomas arise through a multistep accumulation 
of genetic aberrations leading to a selective growth advantage of the malignant clone. 
Recurrent translocations that occur during the different stages of the B-cell 
differentiation are initial steps of this malignant transformation and are considered 
necessary but not sufficient. Thus, further genetic and /or environmental stimuli are 
required for a full malignant transformation. Specific molecular events with a 
potential to transform an autoimmune B cell into a neoplastic cell remain unidentified, 
although some potential molecular targets have been proposed. Two such factors are 
the B-cell activating factor of the TNF family (BAFF) and the cytokine A proliferating-
inducing ligand (APRIL). The former, BAFF, plays a vital role in the B-cell maturation 
and the proper elimination of auto-reactive B cells and increased levels of BAFF are 
expressed in sera and in inflamed tissues of several inflammatory conditions including 
SLE, SS and RA. Thus, mechanisms related to BAFF functions and/or levels may 
constitute a link between autoimmunity and lymphoma.[96, 192]  Expression of APRIL 
is observed in connection with tumors, for example DLBCL, and has the ability to 
potentiate growth of malignant neoplastic cells. It is also expressed in the sera of 
some RA and SLE patients. A recent report from Löfström et al.[261] noted a high 
expression of APRIL in DLBCLs of SLE patients and in a subset of RA patients with 
high accumulated RA disease activity. The authors concluded that this may indicate 
an influence of APRIL in the lymphoma development of these particular subsets of 
rheumatic diseases, alternatively that the observation reflects a dysregulation of APRIL 
in these patient groups.  
 
Another potentially important link between autoimmunity and lymphoma 
development is the chronic B-cell stimulation that occurs in the germinal centers (GC). 
The GC centers are histologically distinct sites within the lymph nodes where intense 
proliferation of the mature B cells takes place after encountering their specific antigen 
or T cells. Some of the NHL subtypes, such as DLBCL arise from B cells that have 
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mutated during the germinal center stages. Furthermore, the GC-reaction is crucial for 
the anti-body mediated immune responses and is thereby an important mechanism 
also for autoimmunity. Thus, the development of some particular lymphoma subtypes 
such as DLBCL in inflammatory conditions characterized by autoantibodies (RA, SLE, 
SS) may be a result of both the chronic B-cell stimulation and the antigenic drive 
during the GC reaction.[96] The autoimmune features, such as defective apoptosis 
may further result in an impaired T-cell immunosurveillance which could enhance a 
neoplastic development. There is also some evidence of a possible common genetic 
basis for RA and lymphoma. Recent studies have found genetic variations in the DNA 
regions (HLA class II) of relevance for both for the risk of RA and the risk of (follicular) 
lymphoma. This may suggest a possible molecular link between these diseases 
although this needs to be further elucidated.[111-112] 
 
Additionally, accumulated inflammatory burden and/or disease severity seems to 
have an impact on the lymphoma development in the inflammatory conditions. As 
already discussed in previous sections, several studies have shown an association 
between inflammatory activity, disease severity and risk of lymphoma, particularly in 
RA, SLE and SS. A potential biological mechanism behind this could be that 
uncontrolled inflammation creates a microenvironment (for example, a different local 
cytokine milieu) further enhancing the chronic B-cell stimulation described above. This 
raises the important question whether the use of anti-inflammatory agents such as 
NSAIDs and glucocorticoids could reduce the risk of lymphoma and/or prevent 
lymphoma development in these patients. Although this remains unclear, data on 
cancer other than lymphoma have provided some potential leads on this subject. It 
has for example been suggested that the reduced risk of colorectal cancer in RA 
patients compared with the general population may be due to the increased use of 
NSAIDs.[188] 
 
With respect to the role of immune-modulatory treatment, one could conclude that 
although there is no strong evidence that traditional DMARDs per se increase the risk 
of lymphoma, it still remains unclear whether therapy further can modulate the 
already existing lymphoma risk. Finally, even though there are no strong signals of 
increased lymphoma risks in RA patients treated with TNFi based on available data, it 
is premature to make conclusions about the risk associated with TNFi in some of the 
inflammatory conditions discussed.   
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2 AIMS 
The overall aim of this thesis was to better understand the nature of the association 
between chronic inflammation and lymphoma development, with particular focus on 
the role of disease severity, inflammatory activity, and immune-modulatory 
treatment.  
 
The specific aims were: 
 
i) To assess whether patients with rheumatoid arthritis (RA) have an increased 
history of lymphoma or other cancer at the time of onset of RA compared with 
the general population. 
 
ii) To explore whether lymphoma risk in RA remains increased in more recently 
diagnosed patients with RA and, if so, to further explore predictors of this risk. 
 
iii) To evaluate the nature of a previously observed lymphoma-protective effect of 
glucocorticoids in RA. 
 
iv) To assess whether the increased lymphoma risk is specific for RA or present 
also in patients with other chronic inflammation such as ankylosing spondylitis 
and psoriatic arthritis. 
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3 METHODS 
3.1 SETTINGS 
Together with the other Nordic countries, Sweden shares the advantage of access to 
census registers and nationwide registers on cancer, hospitalization and health care 
usage of almost 100% coverage. The main holders of these national registers are the 
National Board of Health and Welfare and Statistics Sweden.  
In recent years, an additional type of register has been developed; the quality 
registers. These latter registers have typically been established within and by the 
medical profession with the main purpose to evaluate the quality of a given treatment 
on a group level as well as providing the clinician with individual decision support. The 
quality registers are increasingly used for research as well, providing more detailed 
information on both the diagnoses and on characteristics of each patient treated.[262]  
Chronic diseases, for example RA, with a long follow-up period and a need for 
continuous evaluation of disease progress are well suited for quality registers. 
Furthermore, given the dramatic changes in the treatment of inflammatory/rheumatic 
diseases with the introduction of biological therapies, quality registers have also 
emerged as an important tool in the safety evaluation of such drugs.  
 
Since 1947 each Swedish resident is assigned a unique national registration number 
(NRN) used by all Swedish national registers which enables linkages across different 
registers.[263] The Swedish healthcare system is public and tax funded, making it 
geographically and financially accessible to all residents. All together, these factors 
create an excellent context for epidemiological research using registry data.  
 
3.2 DATA SOURCES USED 
3.2.1 National Registers 
3.2.1.1 The National Patient Register 
The National Patient Register (NPR) is population-based and consists of the Swedish 
Inpatient Register (also referred to as the Swedish Discharge Register) and the 
Outpatient Register. The NPR contains information on hospital discharges (defined as 
at least one overnight hospital stay) by county since 1964 and nationwide since 1987. 
Since 2001 nationwide data from specialist outpatient care (but not primary care) are 
also added to the register. Apart from NRN for each individual, the register holds 
information on all inpatient and outpatient visits with primary and contributory 
discharge diagnoses as assigned by the physician and coded accordingly to the 
calendar year-specific International Classification of Disease, ICD 7-10 as well as date 
of admission and date of discharge. 
Validation studies of the Inpatient Register have shown close to 100% completeness. 
[264] The coverage of the Outpatient Register varies with year and specialty. For 2006 
the assessed average coverage for somatic care was almost 80% (lower coverage for 
private surgical care, and higher for public hospital-based care).[265]  
The validity of the correctness of the discharge diagnoses differs from one diagnosis to 
another. Validation of RA has been shown to have high diagnostic accuracy. In the 
study by Baecklund et al.[197], the RA diagnosis was manually validated  by reviewing 
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the medical records of  > 900 patients recorded with a diagnosis of RA in the NPR 
observing that more than 90% fulfilled the ACR criteria[6] for RA.  With respect to AS 
and PsA, published data on validity is lacking.  However in a pilot study of about 100 
diagnosed AS patients we found a diagnostic accuracy of approximately 80% against 
the modified New York criteria [49] or clinically validated as AS when reviewing the 
medical records  (Karin Hellgren, unpublished data). Among the patients not fulfilling 
the criteria for AS in this validation, the majority had non-inflammatory back pain 
(50%) or suffered from another inflammatory condition, mainly RA (20%). 
 
3.2.1.2 The Swedish Cancer Register 
The Swedish Cancer Registry was founded in 1958 and covers the whole population. 
It holds information on all incident cancers, classified according to the ICD system. 
ICD7 codes are available for all cancer cases from 1958 and the subsequent ICD8-10 
codes are available for each time period respectively, such as ICD10 after 1997. For 
the histological type of cancer, information for the period 1993-2004 is given 
according to ICD-O/2 and from 2005 ICD-O/3, although the histological information 
is less complete than the coding of ICD 7-10. 
Reporting to the register is compulsory for both clinicians and pathologists resulting in 
a high completeness. Approximately 99% of the cancer cases on average are 
morphologically verified.[266] 
 
3.2.1.3 The Cause of Death Register 
 
Already in the 17th century Sweden introduced a nationwide reporting system on 
cause of death, highlighting a long tradition of keeping records of the 
inhabitants.[267] Today’s Cause of Death Register contains information on dates, main 
cause as well as contributing causes of deaths among Swedish residents since 1952. 
The completeness of the register is close to 100%. In 1.8% of the cases (2011)[268] 
death certificates are not available. However, information on these deaths is still 
included in the causes of death register but without any medical information. 
 
3.2.1.4 The Register of Population and Population Changes 
 
The Register of Population and Population Changes is maintained by Statistics 
Sweden and holds census data since 1961.The main information apart from NRN is 
current addresses of residents alive at the end of the year as well as information on 
dates of immigration and emigration (available since 1969). 
 
3.2.1.5 The Prescribed Drug Register 
Since 2005 (1st July) the Prescribed Drug Register provides data for all dispensed 
drug prescriptions to the whole population of Sweden including information on age, 
sex, the prescriber’s profession and practice.[269] The register does not include data 
on drugs used in hospitals, and only partially, drugs that are used in ambulatory care 
but administered in day-care at hospitals. This implicates that biological therapy 
given as infusions in hospital or in day care units are not completely captured in the 
register.  
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3.2.2 Quality Registers 
 
3.2.2.1 The Swedish Rheumatology Register and the Swedish Biologics Register 
The SRQ is maintained by the Swedish Society of Rheumatology and was initially a 
clinical quality register on patients with RA. The main purpose of the register is to 
provide rheumatologists with a useful tool to monitor and evaluate their patients 
both with respect to treatment and to disease control. There are two principal 
components of the register. The early RA component was initiated in 1995 and 
includes incident cases of RA defined as < 18 months of symptom duration with RA 
(≥ 18 years of age, fulfilling the 1987 American Classification of ACR criteria).[6] In 
1999 the register expanded by creating the Swedish Biologics Register, ARTIS.  This is 
a register for patients with rheumatic diseases (not only RA) starting biological 
treatment.  In recent years the register has further expanded to include RA (and 
other rheumatic diseases) with established disease and/or long symptom duration 
irrespective of treatment. 
The SRQ is estimated to include about 60% of newly diagnosed RA from 2007 to 
2009 (although the coverage varies with geographical area). This is based on a 
definition of incident RA as at least two visits with an RA diagnosis in the NPR 
register, with the 2nd visit within one year, no DMARDS six months before first visit 
with RA diagnosis and no previous visit with RA. Conversely, of the estimated 50,000 
prevalent cases of RA in Sweden in 2010, approximately 50% are included in SRQ, 
based on a definition of prevalent RA of ≥ 2 visits with RA in the NPR (personal 
communication Jonas Eriksson unpublished data regarding all the figures above).  
Currently, about 90% of all patients with RA starting a biological agent are included 
in ARTIS.[262]  
3.2.2.2 Information available in SRQ 
At baseline, patients are entered into the register with information on diagnosis, 
rheumatoid factor (RF) status, number of ACR criteria fulfilled (for RA), previous 
treatment and disease activity (DAS28)[31]. For incident RA patients, there is also 
information on date of first symptom of RA and date of diagnosis of RA (i.e. inclusion 
in the register). The patients are then followed up at pre-specified intervals with 
respect to disease activity including CRP, ESR, current therapy, and the rheumatologist 
global assessment of disease activity. All the information is registered by the treating 
rheumatologist. The patients also fill in their assessment of pain and wellbeing (by 
using a visual analogue scale) as well as a Health Assessment Questionnaire (HAQ). 
3.2.2.3 The Swedish Lymphoma Registry (SLR) 
 
The SLR was set up in 2000 and holds information on all patients ≥16 years, diagnosed 
with a lymphoma in Sweden. The register contains information on date of diagnosis 
and subtype of lymphoma. Data are presented in national reports on a regular 
basis.[78] Compared with the Swedish Cancer Register, the SLR holds more 
information on lymphoma subtypes according to the WHO classification.[73] The 
coverage of SLR is approximately 95% of all lymphomas registered in the Swedish 
Cancer Register.  
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3.3 STUDY DESIGNS AND STUDY POPULATION 
3.3.1 Study I 
 
This study comprises two parts; first we assessed the risk of a history of lymphoma 
and other cancers before RA diagnosis, employing a case-control design treating the 
RA patients as cases and their population comparator subjects as controls. Second we 
estimated the risk of lymphoma, and other cancers, in relation to time since RA 
diagnosis employing a matched cohort design treating RA patients as the exposed 
cohort and their comparator subjects as the unexposed cohort (Figure 1).  
 
3.3.1.1 Exposure definition 
Through the SRQ we identified a cohort of patients with incident RA (symptom 
duration < 12 months) from 1997 through 2006 (n=6,745). Each RA patient was 
individually matched to five population comparator subjects (n=33,657) by linkage to 
the Swedish Register of Population and Population Changes. Matching variables were 
gender, year of birth, county of residence and marital status. The comparator subjects 
had to be alive at the time of the diagnosis of their corresponding RA case. 
 
3.3.1.2 Outcome  
 
By linkage of all RA cases and their comparators subjects to the Swedish Cancer 
Register between 1958 through 2006, we identified all registered cases of lymphoma 
and other cancers and their date of diagnosis before and after the diagnosis of RA.  
Malignant lymphomas were defined as non-Hodgkin lymphoma (NHL) including 
chronic lymphocytic leukemia (CLL), and Hodgkin lymphoma (ICD7= 200, 201, 202, 
204.1). In the analyses of all other cancers, malignant lymphomas were excluded. 
Censoring dates for deaths and emigrations were obtained from the Cause of Death 
Register and the Register of Population and Population Changes respectively.  
 
Figure 1 - Schematic picture of study design in study I. 
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3.3.2 Study II 
 
In this population-based cohort study we assessed whether lymphoma risk remains 
increased in more recently diagnosed RA, and further explored the determinants of 
this risk. We also evaluated whether the distribution of lymphoma subtypes among 
these RA lymphomas is different from the one reported in historical RA cohorts or has 
changed compared with the distribution that was observed in historical RA cohorts. 
  
3.3.2.1 Exposure definition 
 
Using data from the SRQ we identified a cohort of patients with incident RA (symptom 
duration ≤ 13 months) from 1997 through 2010 (n=10,367).   
By linkage to the Swedish Register of Population and Population Changes each RA 
patients was matched to five population comparator subjects with respect to gender, 
year of birth and county of residence (n=49,825). Information on inflammatory activity 
(DAS28) was abstracted from visit data in SRQ at; i) baseline, ii) after one year, and iii) 
as a composite measure of DAS28 values during the first year following diagnosis. The 
composite measure was based on the lowest value of DAS28 at three different time 
points; i) 3 months (encompassing 30 to 150 days), ii) 6 months (150 to 270 days), and 
iii) one year (270 to 450 days) post-inclusion. The median number of visits during the 
1st year of follow-up in SRQ was 4 (q1-q3=3-4). 
 
Information on therapy with respect to DMARDs and oral glucocorticoids during the 
first year following RA diagnosis and treatment with TNFi any time during the study 
period was also abstracted from the SRQ.   
 
3.3.2.2 Outcome  
 
As in study I, lymphomas were identified by linkage to the Swedish Cancer Register 
1997-2010. The definition of malignant lymphoma was similar to that of study I. For 
the identified RA lymphomas (n=45), the pathology reports were collected to enable 
categorization into lymphoma subtypes. When the initial lymphoma diagnosis had not 
been confirmed by a hematopathologist and/or not diagnosed according to the WHO 
classification,[73] the paraffin-embedded lymphoma tissues were reviewed and 
classified according to the WHO classification by an experienced haematopathologist. 
This review process was performed in 40 lymphoma cases out of all 45 RA-
lymphomas. To compare the distribution of lymphoma subtypes in RA patients with 
the one in the general population, we used the SLR as reference population.[78] 
 
Subjects with malignant lymphomas occurring before start of follow-up were excluded 
(24 RA patients and 196 comparator subjects). Information on deaths and emigration 
was assembled in a similar manner as in study I.  
 
3.3.2.3 Analyses of lymphoma tissue 
The nationwide Cancer Register contains information about date of diagnosis, the 
reporting pathology laboratory as well as a consecutive specimen code number for 
each diagnosed neoplasm. By using this data, the pathology report and the original 
slides and paraffin-embedded lymphoma tissue were identified and collected. One 
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experienced hematopathologist blinded to all clinical information confirmed the 
lymphoma diagnosis. To review and classify the lymphoma subtypes according to 
the WHO classification,[73] additional sections from the original slides were cut and 
routine immunohistochemistry (IH) staining was performed by using panels of 
antibodies against different antigens (Figure 2).The entire process was performed at 
the Department of Immunology, Genetics and pathology at Uppsala University. 
Similar processes have been applied in other studies.[197, 261, 270]  
The IH staining was performed in Ventana XT BM module (Ventana medical systems, 
Tucson, AZ). 
 
Figure 2 - Process of the validation of lymphoma diagnosis including subtype 
applied in study II, III and IV. 
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3.3.3 Study III 
In this population-based matched case-control study, we sought to further 
characterize the nature of the association between glucocorticoid treatment and risk 
of lymphoma in RA.   
 
3.3.3.1 Definition of Cases and Controls 
 
From the NPR (for this study the inpatient register) we identified 74,651 patients 
with ≥ 1 hospital discharge diagnosis of RA from 1964 through 1994. Through linkage 
of this entire cohort to Swedish Cancer Register from 1964 through 1995, we 
identified 424 RA patients who were diagnosed with a malignant lymphoma after 
the first hospitalization listing RA. From the same underlying cohort we randomly 
selected three RA patients as potential controls, matched for gender, year of birth, 
year of first RA-discharge, and county of residence.  Among these potential controls 
the first of the three controls whose medical record could be identified and who 
fulfilled the ACR criteria [6] for RA was included. The controls had to be alive and 
lymphoma-free at the diagnosis of their index case. Medical records of cases and 
controls were reviewed to confirm the RA diagnosis and the lymphoma specimen 
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were validated, reviewed and (re)classified according to the WHO classification,[73] 
using the same validation process as described in Figure 2. 
After exclusion of cases/controls not fulfilling the inclusion criteria (Figure 3) the final 
study consisted of 378 RA cases and 378 matched controls. 
 
Figure 3 - Schematic description of case identification in Study III. 
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3.3.3.2 Exposure information 
Medical records of all hospital stays and all out-patient care were collected. 
Information on disease characteristics and treatment was abstracted by one of the co-
authors (EB) from each individual's medical records, blinded for the case/control 
status. Controls were followed from onset of RA until the diagnosis of lymphoma of 
the corresponding case. To assess RA disease activity, we abstracted information on 
swollen and tender joint counts, ESR and physicians’ global assessments as recorded 
in the medical files. Based on these variables, RA disease activity was scored as 
inactive, low, medium, or high. Cumulative disease activity for the whole RA period 
was calculated as the area under the curve (AUC) for the duration in months of the 
four different levels of disease activity.  
 
Oral treatment was defined as four or more consecutive weeks on a specified drug. 
The duration of treatment was assessed in months. Treatment with intra-articular 
glucocorticoids was recorded if ever used and further categorized into two groups;        
i) those who received intra-articular glucocorticoids within one month of onset of 
arthritis in more than 50% of documented flares and ii) the remaining patients i.e. 
those who, in more than 50% of documented flares had more than one month 
between arthritis onset and any glucocorticoid injection. Flare was defined as ≥ one 
inflamed joint confirmed at a physical examination and documented in the medical 
record.   
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3.3.3.3 Outcome 
The malignant lymphomas were identified and defined in a similar manner as in 
studies I and II (Figure 2) although CLL was not included. Epstein-Barr virus was search 
for using EBV-encoded RNA (EBER) in situ hybridization. The lymphomas were divided 
into different stages according to the Ann Arbor classification[83-84] by the 
information available in the medical records. 
  
3.3.4 Study IV 
 
In this population-based cohort study we assessed the risk of lymphoma in ankylosing 
spondylitis (AS) and psoriatic arthritis (PsA). We also assessed the overall association 
between TNFi therapy and lymphoma risk in AS and PsA.  
 
3.3.4.1 Exposure definition  
 
From the NPR (for this study the outpatient register) we identified all individuals with 
one or more outpatient visit at a rheumatology or internal medicine department from 
2001 through 2010, with a diagnosis code for AS (ICD10=M45) or PsA (ICD10=M07.0-3, 
L40.5). Patients with these codes or the corresponding codes for juvenile disease 
(M08 and M09) before 18 years of age were excluded. In total, we identified 8,707 
patients with AS and 19,283 patients with PsA. Each individual was matched to five 
population comparator subjects with respect to gender, year of birth and county of 
residence.   
 
By linkage to the Swedish Prescribed Drug Register we collected information on 
prescriptions of DMARDs and oral glucocorticoids from 2005 and onwards. Treatment 
was defined as DMARDs (either of MTX and/or sulfasalazine) or oral glucocorticoids. 
To be defined as treated we required ≥ 2 prescriptions within 6 months as registered 
in the Prescribed Drug Register. From ARTIS we collected information on start on TNFi 
during the study period resulting in 1,908 patients with AS (22% of all identified AS 
patients) and 2,605 patients with PsA (13% of all identified PsA patients) starting their 
first TNFi 2001-2010. 
 
3.3.4.2 Outcome  
 
The malignant lymphomas were identified and defined in a similar manner as in 
studies I and II. By using available ICD10 diagnosis codes as registered in the Cancer 
Register, we further divided the NHLs into subtypes according to the WHO 
classification.[73] As in the above studies, we assembled information on deaths and 
emigration in a similar manner as in studies I and II. For lymphomas occurring in 
patients with AS or PsA treated with TNFi,  the lymphoma specimen were collected, 
reviewed and (re)classified according to the WHO classification using the same 
validation process as described in Figure 2. 
 
Studies I, II and IV were approved by the Ethics Committee at Karolinska Institutet and 
study III was approved by the Ethics Committee at Uppsala University. 
 
 38 
 
3.4 STASTISTICAL ANALYSES 
 
3.4.1 Statistical concepts  
 
3.4.1.1 Logistic regression models 
 
Logistic regression is a method for determining the relationship between 
explanatory (or independent) variables of any kind (continuous, dichotomous or 
categorical) and a dichotomous (for example RA yes/no) coded dependent variable. 
The method is often applied in case-control studies. To assess the influence of an 
explanatory variable on the dependent variable, the odds ratio (OR) is estimated. An 
OR can be defined as the ratio of the odds of an event occurring in one group to the 
odds of it occurring in another group. Thus, being a ratio of a ratio, the OR is different 
from RR (being a ratio of a risk). However OR provides an acceptable approximation 
for RR when disease incidence is rare (a rule of thumb is a disease prevalence of <10%) 
the so-called “rare disease assumption”. For more common outcomes, the odds ratio 
overstates the relative risk, sometimes dramatically.   
 
There are two main groups of logistic regression: conditional and unconditional 
logistic regression. Conditional logistic regression is used if matching of cases to 
controls has been performed, and unconditional if there has been no matching.  
When conditional logistic regression is used, the matched pairs are compared to 
each other. In unconditional logistic regression all cases are compared to all 
controls. 
 
3.4.1.2  Cox proportional hazard models 
Cox regression (or proportional hazards regression) is a method for investigating the 
effect of several variables upon the time that passes before some specified event 
occurs. The method is applied in cohort studies. A typical medical example would 
include covariates such as treatment assignment, as well as patient characteristics 
such as age, gender, and co-morbidities in order to control for confounding. The Cox 
regression estimates the hazard ratio (HR) which can be defined as the ratio of the 
number of new cases of a disease per population at risk per unit time comparing 
exposed to unexposed. A key assumption of the Cox regression model is the 
proportional hazard assumption. This means that the survival curves for two strata 
must have hazard functions that are proportional over time (i.e. constant relative 
hazard). 
 
3.4.2 Statistical analyses used 
 
In studies I-III we used Cox’ proportional hazard model to estimate the hazard ratios 
expressed as relative risks and to calculate 95% confidence intervals (CI). To test for 
the proportional hazard assumption we introduced an interaction term between the 
exposure and the log of follow-up time. In studies I and IV we used conditional logistic 
regression. Odds ratios were calculated, expressed as RRs with 95% CI. The matching 
variables were included in all models used. To estimate whether there was a 
difference between the estimated RRs in the different calendar periods of RA duration 
in studies I and II we performed a Wald test. 
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All analyses were performed using the SAS software package, Version 9, SAS institute, 
Cary, North Carolina, USA. 
 
3.4.2.1 Study I 
 
To assess the risk of having a lymphoma or cancer overall before the diagnosis of RA, a 
first primary lymphoma or other cancer respectively was considered the exposure. All 
cases of lymphoma or other cancers occurring within 90 days after RA diagnosis (i.e. 
inclusion in the SRQ) were included in the analysis as these cases were considered as 
prevalent rather than incident.  
 
To assess the risk of having a lymphoma or cancer overall, in relation to time since RA 
diagnosis, the RA patients were considered as the exposed cohort and the comparator 
cohort as the unexposed cohort. Time since diagnosis of RA (defined as inclusion date 
in the SRQ) was used as time-scale. To assess for the risk of lymphoma in relation to 
time since RA (0-<3, 3-<6 and 6-10 years), we used time-dependent covariates. 
Patients with a history of a lymphoma or other cancer at the time of the RA diagnosis 
were excluded.  
 
3.4.2.2  Study II 
In study II, RA was the exposure of interest and lymphoma was the outcome. To 
assess whether lymphoma risk in RA had changed over calendar period of disease 
onset, we assessed the role of duration of RA (0-<6, 6-14 years) as a function of 
calendar period (1997-2003, 2004-2010) by using time-dependent covariates. Each 
cohort member contributed time as person-years from start of follow-up (diagnosis of 
RA) until lymphoma, death, emigration or end of follow up (31th December 2010) 
which came first. To avoid that an underlying lymphoma was misclassified as an 
incident RA, we excluded all person-time and all events during the first 90 days of 
follow-up.  
In the assessments of lymphoma risk in relation to inflammatory activity, DMARDs and 
oral glucocorticoids during 1st year following RA diagnosis, all person-time and all 
events with less than one year of follow up were excluded (9,533 RA patients, 41 
lymphomas). When estimating lymphoma risk in relation to TNFi, we treated TNFi as a 
time-varying covariate so that patients contributed to the TNFi-naïve group until start 
of their first TNFi and to the TNFi exposed group thereafter. In all the treatment 
analyses we additionally adjusted for inflammatory activity during the 1st year of 
follow up.  
When estimating RRs for subtypes of lymphoma, we used the ICD10 codes as 
registered in the Swedish Cancer Register. The rationale for this was that through SLR, 
we only had access to the overall rather than age-specific distributions of subtypes 
and because the age in SLR was younger that the age in our RA cohort.  
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3.4.2.3 Study III 
The exposure of interest was therapy with glucocorticoids in RA patients in relation to 
lymphoma risk. The association was assessed overall, adjusted and stratified by the 
AUC of cumulative disease activity (in quartiles of AUC) and DMARD use (never/ever). 
We also assessed duration of steroid treatment (more or less than 2 years), timing of 
first steroid treatment (more or less than five years of RA duration), mode of 
administration, and intra-articular treatment type (i or ii, as described in section 
3.3.3.2).   
 
3.4.2.4 Study IV 
 
Main exposures of interest were AS/PsA, and TNFi. The outcome of interest was 
lymphoma. In all analyses, we excluded all person time and all events during the first 
90 days of follow-up in order to exclude underlying lymphomas misclassified as AS or 
PsA (constituting the reason for the visits that lead to inclusion into the cohorts under 
study).  
Analyses were additionally performed using a stricter definition of the AS/PsA study 
population, requiring ≥ 2 outpatient visits with AS and PsA, respectively. To further 
limit the risk of AS/PsA misclassification, the analyses were also performed excluding 
all patients ever recorded with an RA diagnosis as registered in the outpatient register. 
Start of follow up was the date of the first outpatient visit for AS and PsA patients and 
the corresponding date for their comparator subjects until the first of lymphoma, 
death, emigration or end of follow up (31th December 2010).  
 
When assessing the risk in relation to anti-rheumatic treatment (other than TNFi), 
start of follow up was defined as date of the 2nd recorded prescription (from the 
Prescribed Drug Register) of each drug for the AS and PsA patients (and corresponding 
date for the comparator subjects). The crude incidences of lymphoma in AS and PsA 
patients exposed to TNFi therapy were calculated counting time from the start of the 
first TNFi until the first of; lymphoma diagnosis, death, emigration or end of follow-up 
(31st December 2010). Due to small numbers of events (<5) we abstained from 
assessing relative risks. 
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4 RESULTS 
 
4.1 STUDY I 
 
Risk of lymphoma and cancer overall before diagnosis of RA 
Twelve of the RA patients (0.2%) and 89 (0.3% of all comparator subjects) had a 
history of a malignant lymphoma, resulting in a RR of 0.7 (95% CI 0.4-1.2). 
At the time of RA diagnosis, 356 (5.3%) of the RA patients and 2,240 (6.6%) of the 
general population subjects had a history of any other first primary cancer, 
corresponding to an RR of 0.8 (95% CI 0.7-0.9). RRs for both lymphoma and cancer 
overall remained virtually similar in stratified analyses according to gender, RF status, 
age at RA diagnosis, year of RA diagnosis, and time period between lymphoma/cancer 
diagnosis and RA diagnosis. There was a significantly reduced risk of a history of 
malignant melanoma and a non-significant reduced risk of lung and breast cancer in 
the RA patients. A history of colorectal, non-melanoma skin and prostate cancer was 
equally common among RA patients and their population controls (Table 7).  
 
 
Table 7 - Relative risk of a history of cancer overall and site-specific malignancies, 
before the diagnosis of RA in an incident RA cohort (n= 6,745) compared with their 
matched comparator subjects (n=33,657) 1997-2006.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1Not including malignant lymphoma 
 
 
 RA patients 
n=6,745 
Population 
controls 
n=33,657 
RR (95% CI) 
Cancer overall 1 
 
356 2,240 0.8 (0.7-0.9) 
Breast cancer 95 587 0.8 (0.6-1.0) 
Prostate cancer 45 273 0.8 (0.6-1.3) 
Colorectal cancer 40 237 0.8 (0.6-1.2) 
Malignant melanoma 15 149 0.5 (0.3-0.8) 
Non-melanoma skin cancer 14 89 0.8 (0.4-1.4) 
Malignant lymphoma 12 
 
89 0.7 (0.4-1.2) 
Lung cancer  3 46 0.3 (0.1-1.0) 
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Risk of lymphoma and cancer overall after diagnosis of RA 
After RA diagnosis, 19 lymphomas (crude incidence 65 [95% CI 39-101] per 100,000 
person-years) occurred among the 6,720 RA patients compared with 53 lymphomas 
(crude incidence 37 [95% CI 27-48] per 100,000 person-years) among the 33,063 
comparator subjects. The RR of lymphoma was 1.8 (95% CI 1.0-3.0).  
There was a suggestive trend of increasing RRs during the first 10 years after diagnosis 
of RA that was not statistically significant (p =0.15, Figure 4) 
 
Counting from RA diagnosis, 302 of the RA patients, and 1,205 of the comparator 
subjects were diagnosed with any other first primary cancer (excluding lymphoma), 
corresponding to a RR of 1.2 (95% CI 1.1-1.4). The overall 20% increased risk was 
driven by an elevated risk within the first years after RA diagnosis, mainly due to 
elevated risks for prostate and lung cancer (Figure 4). 
 
 
Figure 4 - Relative risks of lymphoma and cancer overall as a function of time (years) 
before and after diagnosis of RA. 
 
 
 
 
4.2 STUDY II 
 
We identified 45 lymphomas among the RA patients (n=10,367) and 126 lymphomas 
among the comparator subjects (n=49,825).  
 
Risk of lymphoma in RA patients with respect to disease duration and year of RA 
onset                                                                                                                                               
Among the RA patients, the crude incidence of lymphoma was 76 [95% CI 56-102] per 
100,000 person-years compared with 44 [95% CI 37-34] per 100,000 person-years in 
the comparator subjects resulting in an RR of lymphoma of 1.7 (95 % CI 1.2-2.4). The 
point estimate of relative risk of lymphoma was numerically higher 6-14 years after RA 
onset than during the first 6 years, although the difference did not attain statistical 
significance (p=0.12). When calendar period of RA diagnosis was added to the model 
(in one-year bands) no effect of this parameter was observed (p for calendar 
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period=0.5). A similar pattern was observed when RRs were cross-tabulated according 
to year of onset and time since RA diagnosis (Table 8).  
Table 8 - Relative risks of malignant lymphoma in an incident RA cohort (=10.367) 
compared with individually matched comparator subjects (=49,825) 1997-2010 with 
respect to time since RA duration overall, and year of RA onset. 
1Year of inclusion in SRQ 2We abstained from assessing RR due to small number of events. 
 
Risk of lymphoma in relation to disease characteristics and inflammatory activity  
When we estimated the lymphoma risk in mutually exclusive groups of accumulated 
inflammatory activity (DAS28) during the first year following RA diagnosis we observed  
a tendency (however non-significant) towards higher risks in the group of patients 
having a DAS28≥ 3.2 at start and at all the follow-up visits registered in the SRQ during 
1st  year in comparison to those with a DAS28 at all available visits during the 1st year   
< 3.2 (with the remainder of the RA cohort as reference group, Table 9).  
Risk of lymphoma in relation to anti-rheumatic therapy                                                     
Twenty-three out of 41 (56%) of the RA-lymphomas had been treated with MTX 
during the first year of follow up compared with 6,370 (67%) of the entire RA cohort, 
resulting in an RR of lymphoma of 0.8 (95% CI 0.4-1.6).  On the contrary, treatment 
with oral glucocorticoids in the first year following RA diagnosis was associated with a 
non-significant decreased risk of lymphoma; RR= 0.6 (95% CI 0.3-1.0) based on 20 
(49%) of the RA lymphomas being treated oral glucocorticoids compared with 6,149 
(65%) of the RA cohort as a whole. 
Six out of 45 RA lymphomas (13%) had been treated with TNFi anytime during the 
study period compared to 2,314 (22%) of the entire RA cohort. This yielded an RR of 
1.1 (95% CI 0.5-2.8) compared with TNFi-naïve RA patients. Adjusting for inflammatory 
activity did not appreciably change the results in any of the above analyses (Table 9). 
 
Year of RA 
diagnosis1 
 
Time period since RA diagnosis (years) 
RR (95% CI)  
(N lymphomas RA patients/ 
comparator subjects) 
 
Total follow-up 
period 
RR (95% CI) 
 
 
0-<6 6-14 
1997-2003 
 
1.3 (0.8-2.3) 
(14/49) 
 
2.4 (1.4-4.3) 
(17/32) 
1.8 (1.2-2.8) 
(31/81) 
 
2004-2010 
 
1.5 (0.9-2.8) 
(13/42) 
 
(1/3)2 
 
1.5 (0.8-2.7) 
(14/45) 
Total study period 
1997-2010 
 RR ( 95% CI) 
1.3 (0.9-2.1) 
(27/91) 
2.8 (1.7-4.7) 
(18/35) 
1.7  (1.2 -2.4) 
(45/126) 
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Table 9 - Relative risks of lymphoma in incident RA patients (n=9,533) 1997-2010 
with respect to inflammatory activity, use of methotrexate or oral glucocorticoids 
during first year following RA diagnosis and exposure to TNFi any time during 
follow- up compared with all other RA patients. 
1This analysis was based on the entire RA cohort (=10,367), number of lymphomas=45 
Distribution of lymphoma subtypes in patients with contemporary RA                           
Chronic lymphocytic leukemias comprised a considerably smaller proportion (4%) of 
all lymphomas in our RA cohort compared with the SLR (24%). However, comparing 
the incidence to that of the comparator subjects, the decreased risk was not 
statistically significant; RR for CLL= 0.4 (95% CI 0.1-1.5). Hodgkin lymphomas were 
more common in the RA cohort (19%) versus SLR (10%) and the historical RA cohort 
(6%) corresponding to an RR of 6.4 (95% CI 2.2-18) compared with the comparator 
subjects. The proportion of DLBCLs was 37% compared with 32% in the SLR, both of 
which were lower than the corresponding proportion in the historical RA cohort 
(48%).  
4.3 STUDY III 
 
Oral glucocorticoid treatment  
Of the 373 cases (missing information on glucocorticoids in 5 cases), 183 (49%) 
subjects and of the 378 controls 217 (57%) subjects had been treated with oral 
glucocorticoids. The mean duration of RA until lymphoma diagnosis for cases treated 
with oral glucocorticoids was similar to those who were not treated (treated: 21 years, 
range 2-54 years, not treated: 19 years, range 1-55 years). Overall treatment with oral 
glucocorticoids was associated with an RR of lymphoma of 0.6 (95% CI 0.4-0.9) 
adjusted for DMARD treatment and disease activity as previously reported.[197]   
 
A total duration of oral glucocorticoid treatment less than 2 years was not associated 
with lymphoma risk (RR=0.9; 95% CI 0.5-1.5), whereas total treatment longer than two 
Inflammatory activity during first 
year following RA diagnosis 
N of lymphomas 
(%)                      
Total = 41 
N of RA 
patients (%)  
Total =9,533 
RR (95% CI) 
DAS28≥3.2 at every measure point  9 (22) 1,210 (13) 1.9 (0.9-4.1) 
DAS28<3.2 at every measure point  7  (17) 1,311 (14) 1.3 (0.5-2.9) 
Remaining group of the RA cohort 25 (61) 7,012 (73) 1 (ref) 
Anti-rheumatic therapy during  
first year following RA diagnosis  
   
Methotrexate  (yes vs. no) during 
first year following RA diagnosis 
23(56) 
 
6,370 (66) 0.8 (0.4-1.6)  
Oral glucocorticoids  (yes vs. no) 
during first year following RA 
diagnosis 
 
20 (49) 6,149 (65) 0.6 (0.3-1.0)  
TNFi during follow-up (yes vs.no, 
time-dependent)1 
6 (13) 2,314 (22) 1.1 (0.5-2.8)    
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years was associated with a lower lymphoma risk (RR= 0.4; 95% CI 0.3-0.7). The RR of 
lymphoma was similarly reduced in the group of patients starting oral glucocorticoids 
within the first 5 years after diagnosis of RA compared with the group of patients 
starting treatment later in their RA course (RR in both groups = 0.6; 95% CI 0.4-1.0, 
adjusted for disease activity and DMARD therapy). 
 
Oral glucocorticoid treatment in relation to disease activity  
Within each quartile of cumulative RA disease activity, steroid treatment was 
associated with a lower lymphoma risk. For instance, oral steroid treatment in the 
highest quartile of disease activity was associated with an RR of 12 (95% CI 5.0-28), 
compared to an RR of 30 (95% CI 11-76) for the same quartile of disease activity but in 
the absence of oral steroid treatment. 
 
Oral glucocorticoid treatment in relation to lymphoma characteristics  
In the analyses by lymphoma subtype we noted a significantly reduced risk of DLBCL 
(crude RR=0.6; 95% CI 0.4-0.9) and a non-significantly reduced risk of follicular 
lymphoma (crude RR=0.7; CI 95% 0.2-2.3) following treatment with oral 
glucocorticoids, whereas the crude RR for all other subtypes combined was 0.8 (95% 
CI 0.5-1.3). At the time of lymphoma diagnosis, 84 (22%) of the cases and 125 (26%) of 
the controls were treated with oral glucocorticoids. The symptoms leading to 
lymphoma diagnosis, as well as the occurrence of B-symptoms (fever, weight loss, 
night sweats) were similar for cases on glucocorticoids and not on glucocorticoids, 
respectively, at the time of lymphoma diagnosis.  
 
Intra-articular glucocorticoids  
Overall, treatment with intra-articular glucocorticoids was associated with a 
decreased lymphoma risk; RR= 0.4 (95% CI 0.2-0.6), adjusted for DMARDs and disease 
activity. However, this risk reduction was restricted to those patients who received 
intra-articular glucocorticoids within one month of onset of arthritis in more than 50% 
of documented flares (group i), RR= 0.2 (95% CI 0.1-0.4), whereas the RA patients in 
group ii (i.e. those patients who received intra-articular glucocorticoids  after more 
than one month’s delay in more than 50%  of reported flares had a RR of lymphoma of 
2.6 (95% 1.1-6.2).  
 
4.4 STUDY IV 
We identified 14 lymphomas among the AS patients (n=8,707) and 75 lymphomas 
among the comparator subjects (n=41,092). For PsA we found 45 lymphomas among 
the patients (n=19,283) and 175 lymphomas among the comparator subjects 
(n=92,684). 
Risk of lymphoma in relation to the general population                                                            
The RR of lymphoma in AS patients compared with the comparator subjects was 0.9 
(95% CI 0.5-1.6). Excluding all patients ever recorded with a diagnosis code of RA (12% 
of all AS patients) resulted in a virtually unchanged relative risk. For the patients with 
PsA, RR of lymphoma was 1.2 (95% CI 0.9-1.7). Excluding all patients ever recorded 
with a diagnosis code of RA (17% of all PsA patients) yielded an RR of 1.0 (95 % CI 0.6-
1.4). Applying a stricter case definition (i.e. demanding ≥ outpatient visits with AS or 
PsA) resulted in an RR of lymphoma of 0.9 (95% CI 0.5-1.6) for AS and an RR of  
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1.3 (95% CI 0.9-1.9) for PsA. Subset analyses by gender, age, calendar period and 
duration of time between start of follow-up until lymphoma diagnosis resulted in RRs 
largely similar to the overall RR both in AS and in PsA. 
Risk of lymphoma in relation to DMARD therapy 
Analyses restricted to AS patients who were treated with DMARDs did not reveal any 
significantly different RRs compared to the overall risk. On the contrary, for the PsA 
patients, treatment with MTX and/or sulfasalazine was associated with a significantly 
increased risk of lymphoma compared with the comparator subjects (Table 10). When 
excluding patients ever recorded with a RA diagnosis code, we observed similar 
results; RR for DMARDS=1.9 (95% CI 1.1-3.7). Use of oral glucocorticoids was not 
associated with any increase occurrence of lymphoma neither in AS nor in PsA (Table 
10). 
 
  
Table 10 - Relative risks and crude incidences of lymphoma in the Swedish cohort of 
AS (n=6,415) and PsA (n=14,088) patients compared with their comparators subjects 
with respect to anti-rheumatic treatment 2001-2010. 
                                                                                                                                                                                    
 
All analyses are based on a stricter case exposure definition, i.e. requiring two or more 
outpatient specialist visits with AS or PsA respectively 1Treatment defined as ≥ two 
prescriptions of the drug within 6 months registered in the Prescribed Drug Register 2005-
2010. 2Defined as treatment with either methotrexate and/or sulfasalazine.   
 
 
Incidence of lymphoma in relation to TNFi therapy   
Among the TNFi treated AS patients 2 lymphomas occurred (crude incidence 25 [95% 
CI 3-93] per 100,000 person-years) compared with 12 lymphomas (crude incidence 27 
[95% CI 14-48] per 100,000 person-years) among non-TNFi treated AS patients. 
Applying a stricter AS-case definition (Table 10) did not change the crude incidence. In 
both of the 2 AS lymphomas the AS and the lymphoma diagnoses could be confirmed 
from the medical records and from the pathology reports.  
 AS 
N of lymphomas  
(N of patients 
treated) 
RR (95% CI) 
 
PsA 
N of lymphomas       
(N of patients 
treated) 
RR (95% CI) 
Overall 12 (6,415) 0.9 (0.5-1.6) 37 (14,088) 1.3 (0.9-1.9) 
DMARDs 1,2                3 (2,144)  1.2 (0.3-4.3) 15 (7,648) 1.7 (1.0-3.1) 
Oral 
glucocorticoids1 
0 (1,177) - 3 (4.082) 0.6 (0.2-2.0) 
  Crude 
incidence/ 
100,000 person-    
years 
 Crude 
incidence/ 
100,000 
person- years 
Overall 11/6,415 28 (14-50) 37/14,088 44 ( 31-61) 
TNFi    2/1,752 28 (3-102)   5/2,343 52 (17-122) 
TNFi -naïve    9/6,146 27 (12-52) 32/13,918 43 (29-61) 
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For the TNFi treated PsA patients, we observed 8 lymphomas (crude incidence 73 
[95% CI 34-144] per 100,000 person-years) compared with 37 lymphomas (crude 
incidence 37 [95% CI 26-52] per 100,000 person-years) in the comparator subjects. In 
a second approach, in which we applied a stricter case definition of PsA (i.e. requiring 
at least 2 outpatient visits with PsA), the crude incidence in the subset treated with 
TNFi was 52 [95% CI 17-122] per 100,000 person-years (Table 10). However, validation 
using medical records revealed that 3 out of the original 8 PsA lymphoma patients 
actually fulfilled the ACR classification criteria [6] for RA and were clinically evaluated 
as RA patients, and thus misclassified as PsA patients in the National Patient Register. 
In a third approach, we excluded these 3 PsA lymphoma cases from the original 
numerator and estimated the crude incidence based on all TNFi-treated PsA patients 
who also had a PsA diagnosis in SRQ (denominator, n=1,987). We then observed a 
crude incidence of lymphoma of 64 [95% CI 21-151] per 100,000 person-years. Finally, 
the revalidation of the lymphoma specimens of the remaining 5 PsA lymphoma cases 
revealed that one of these patients did not have a lymphoma diagnosis. When this 
patient was excluded from the analysis, this resulted in a lymphoma incidence rate of 
52 [95% CI 14-131] per 100,000 person-years. 
 
Distribution of lymphoma subtypes 
When categorizing the observed lymphomas into different subtypes according to 
ICD10 diagnoses registered in the cancer register, we did not find any increased 
proportion of any specific subtype; apart from a slightly higher proportion of DLBCLs in 
the AS patients compared with their comparator subjects (based on small numbers in 
each subgroup of lymphoma). There was no increased proportion of T-cell lymphoma 
in PsA patients compared with the general population (Table 11). 
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Table 11 - Distribution of lymphoma subtypes in AS and PsA patients compared with 
their comparator subjects 2001-2010. 
 
 
1Lymphoma subtype as registered according to ICD10 codes in the Swedish cancer register 
DLBCL= Diffuse large B-cell lymphoma, NHL= non-Hodgkin lymphoma, HL= Hodgkin 
lymphoma, CLL= chronic lymphocytic leukemia 
Lymphoma 
subtypes1 
 
AS patients 
lymphoma 
N =14  
N of lymphomas 
(%) 
General 
population 
lymphoma 
N=75 
PsA patients 
lymphoma 
N=45 
General     
population 
lymphoma 
N=175  
B cell     
DLBCL 7 (50) 22 (29) 19(42) 59 (34) 
Follicular 
lymphoma 
0 (0) 11 (15) 3 (7) 24 (14) 
Other B cell  1 (7) 7 (9) 5 (11) 19 (11) 
T cell 1 (7) 3 (4) 1(2) 9 (5) 
NHL unspecified 0(0) 6(8) 7 (16) 13 (7) 
HL 0(0) 6(8) 5 (11) 5 (3) 
CLL 4(29) 20(27) 5(11) 44 (25) 
Lymphoma UNS 1(7) 0 (0) 0 (0) 2 (1) 
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5 GENERAL DISCUSSION 
5.1 METHODOLOGICAL ISSUES 
5.1.1 Study Design 
Choosing the appropriate study design is a give- and-take between validity (whether 
the study is able to answer the question it is intended to answer) and efficiency. The 
gold standard for analytic studies is an experimental design. However, for many 
research questions, an experimental study is considered unethical (such as to expose 
participants deliberately to a potentially harmful exposure) or inappropriate for other 
reasons. Thus, in many cases an observational study design is the best or the only 
choice. Two observational designs commonly used in epidemiology (and in this thesis) 
are cohort and case-control study designs. 
 
In cohort studies, participants are defined on the basis of a particular exposure. 
Cohort studies can be prospective (participants are included before or at the time of 
exposure) or retrospective (the study begins after the exposure). However, also in 
retrospective designs, information bias (such as recall bias) can be minimized as long 
as the exposure information is recorded in a prospective manner and registered 
independently of the outcome (this is often the case in register based studies such as 
the studies in this thesis).   
 
Cohort studies are well-suited to examine disease after rare exposures and to study 
how the effect of an exposure changes over time. They also allow for the estimation 
and comparison of incidence rates and allow measures of the absolute risk of 
developing a disease after an exposure. The design may however require a large 
number of participants and a sufficiently long period of follow-up time when only a 
small proportion of the participants at risk actually develops the outcome. This can 
make them expensive and time-consuming. Loss of follow-up may also be a problem. 
Here, register-based retrospective cohort studies provide an advantage.   
 
In case-control studies, participants are included on the basis of whether they have 
developed the disease of interest or not. Exposure is compared between those with 
the disease (cases) and without (controls) to assess whether an association exists. As 
in cohort studies, exposure information can be recorded prospectively which is 
preferable both to minimize recall bias and to ensure that case status and exposure is 
independent of one another. The major weakness of a case-control study is a proper 
selection of cases and controls and to avoid bias in assessment of the exposure. Case-
control studies have the advantages of being cost-efficient as the number of 
participants can be smaller. They are well-suited for studying rare diseases, and 
because entrance into a case-control study is based on disease status, they can 
examine the association between multiple exposures and the disease of interest. 
However, they do not allow estimations of multiple diseases associated with one 
exposure. Furthermore, the data collected in a case-control study cannot be used to 
calculate the incidence rates, nor absolute risks for disease due to an exposure unless 
the underlying cohort is known or the exposure prevalence can be estimated.  
 
 50 
 
Studies I, II and IV are cohort studies, with prospectively recorded exposure 
information, independently from the outcome of interest. In studies I and II, the 
exposure information was collected from the SRQ, and in study IV from the outpatient 
register of the NPR. By using population-based information we included large cohorts 
of exposed individuals allowing us to assess stable risk estimates and (for studies I and 
II) to estimate relative risks stratified by time period.  In study I, we additionally 
applied a case-control design when assessing the lymphoma/cancer risk before the 
onset of RA. By incorporating two different designs in the same study, we could 
estimate risks at different time points before and after diagnosis of RA in order to 
investigate the possible impact of shared genetic susceptibility or common risk factors 
behind RA lymphomas. 
 
In study III, the case-control design allowed us to control for a number of potential 
confounders and to estimate stable risk estimates of some major lymphoma subtypes.  
 
5.1.2 Validity 
Validity of a study can be divided into two components, internal validity (i.e. can the 
findings within the study population be trusted or absence of systemic or random 
errors) and external validity (i.e. generalizability of the findings to other populations). 
The major threats to the internal validity can be classified into three main categories; 
selection bias, information bias and confounding. 
 
Selection bias 
Selection bias is introduced if exposure status influences the selection of cases and 
controls in a case-control study or if the association between exposure and outcome 
differs between those that participate in a study versus those that do not participate. 
In study III, the matched controls were selected from the same underlying prevalent 
RA-cohort identified within the inpatient register i.e. both cases and controls had at 
any point been hospitalized with a RA diagnosis. Thus, if a control had developed a 
lymphoma they would have been a case. Restricting the study to cases and controls 
who at any point had been hospitalized with RA may have led to a selection of 
patients with a more severe disease. That would, however, affect the external rather 
than the internal validity. 
 
In the case-control analysis of study I we assessed the risk of lymphoma or cancer 
overall before the RA diagnosis the point estimates was just below 1. This could be 
explained by a bias towards a selection of cancer/lymphoma patients with a good 
prognosis, i.e. those who die due to their cancer do not have the chance to develop 
RA. Conversely, it may be that patients with a short life expectancy (for example an 
advanced cancer) are less likely to be included in a register as SRQ with an intended 
long follow-up period. This again could lead to a selection of “healthier” RA patients 
in studies I and II and thereby an underestimation of the true lymphoma risks. Again 
this would have an impact on the external rather than the internal validity. 
 
In study IV, the exposed (AS and PsA) cohorts were assembled from the outpatient 
register of the NPR. Since the registration in the NPR is population-based (with 
outpatient specialist visits accessible to all Swedish residents) the AS and PsA 
cohorts were recruited from outpatient visits spanning from university hospital 
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clinics to small outpatient clinics, thereby reducing the risk of choosing patients with 
a particular phenotype of AS or PsA (for example those with a more complicated and 
severe disease managed solely at a university hospital). On the other hand, as the 
outpatient register doesn’t hold information on primary care visits, AS or PsA 
patients managed only at their general practitioner were not included. Furthermore, 
as no dates of disease onset are available in the NPR, the patients of these cohorts 
must be considered as prevalent cases. 
 
Detection Bias  
A newly diagnosed RA patient is typically subjected to some clinical work up, such as 
a chest X-ray and blood samples, both for evaluating the RA diagnosis and for 
preparing for start of DMARD treatment. This may lead to detection of latent 
diseases such as cancer. Such detection bias is likely to affect risk estimates 
occurring around and shortly after RA diagnosis.  This could partly explain the early 
increase in overall cancer risk following RA diagnosis in study I, but could not readily 
explain the persistently increased lymphoma risk seen during a longer follow-up 
period. Furthermore, a closer surveillance of the RA, AS or PsA patients may 
potentially lead to an earlier detection of an indolent lymphoma with few symptoms 
such as a CLL. However, in none of the studies (II and IV) we observed any increased 
occurrence of CLL. By contrast, increased risks were primarily associated with HL and 
DLBCL. 
 
Information bias 
Information bias can be defined as incorrect measurement of exposure and/or 
outcome (also called misclassification) and may occur in any study. Misclassification 
of either exposure or outcome can be differential or non-differential depending on 
whether measurement error of one variable correlates with the measurement of 
another variable. Non-differential misclassification is random and will typically dilute 
an observed association between the exposure and the outcome. Differential 
misclassification occurs when the misclassification of exposure in a subject is 
affected by the disease status or vice versa. This can bias the relative risk towards or 
away from the null. An example of differential misclassification in case-control 
studies is recall bias (i.e. a patient may overestimate their exposure to a potential 
harmful risk factor due to their disease status). 
Although validation studies of the population-based NPR show that the majority of 
the diagnoses are correct [264], there is a certain degree of misclassification of 
diagnoses. This became evident in study IV where confirmation of the PsA diagnoses 
in the patients exposed to TNFi (and developing a lymphoma) turned out to be 
correct in 5/8 (63%) of the PsA-cases when we validated the diagnosis against the 
medical records. However, in study IV we also had access to information from ARTIS, 
enabling estimations of lymphoma incidences rates in rheumatologist-diagnosed AS 
and PsA diagnoses of patients receiving TNFi. In study IV, we also tried to reduce 
potential misclassification bias both by applying a stricter exposure definition i.e. 
requiring at least 2 outpatient visits with AS/PsA diagnosis as well as excluding all 
patients ever recorded with a diagnosis code for RA (given the obvious but 
challenging overlap between these two diagnosis). This resulted in largely similar 
relative risks. Nevertheless, the potential misclassification of exposure remains a 
limitation of study IV. Furthermore, to avoid including an underlying undiagnosed 
lymphoma (which could be the reason for the visits that lead to inclusion in the 
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cohorts under study) we excluded all person-time and all events during the first 90 
days of follow-up. 
 
As for the outcome status (in all studies) and the exposure information (in the first 
part of study I), this was register-based information from the Swedish Cancer 
Register which has a high validity, although it must be remembered that 
misclassification to some extent exists in all registers.  
 
Confounding 
The definition of a confounder is a factor that is associated with both the disease 
and the exposure but not an effect of the exposure. When unequally distributed 
among exposed/non-exposed or cases/controls, a confounder may bias the relative 
risk away from or towards the null. There are several methods to control for 
confounding in a study design (randomization, restriction, matching) and in the 
statistical analyses (stratification and adjustment). However, to successfully control 
for confounding requires that the confounder a) is a priori known b) is measurable. 
In register-based studies information on potential confounders is often limited.  
In studies I and II, we could adjust for the matching variables in statistical models and 
stratify by RF, age and calendar period of onset in RA as well as duration of RA disease. 
We did not have information about lifestyle factors such as smoking; information that 
probably would influence the observation of increased RR of lung cancer following RA 
diagnosis since smoking is a common risk factor for both conditions.[11, 271-273] The 
same holds for study IV, where we could adjust only for the matching variables and 
some basic characteristic of the AS/ PsA diseases. On the other hand, few risk factors 
shared by lymphoma and RA (besides immune-suppression) are established.[147]  
 
A particular type of confounding, confounding by indication (or sometimes called 
channeling bias) arises from the fact that individuals who take a medication are 
different from those who do not. In the studies of this thesis, this can be illustrated 
by the challenge to assess the link between therapy, inflammatory activity and 
lymphoma risk in RA, since patients receiving systemic treatment have a more active 
and/or a more severe disease. This emphasizes the importance of taking both 
disease severity and treatment into account. In study II, we had access to visit data 
in the SRQ that enabled for adjustments for inflammatory activity during the first 
year following RA diagnosis in the treatment analyses performed.  In study III, the 
extensive data collected on characteristics of the RA disease, treatment and disease 
severity enabled us to evaluate several possible confounders of the association 
between glucocorticoids and risk of lymphoma in RA, taking accumulated 
inflammatory activity and concomitant DMARD therapy into account. 
 
In study III, cases and controls were matched on age, gender and residency as well 
as year of first RA hospitalization. In this matching procedure, we could not match 
for the exact RA duration, as date of onset was not available when selecting the 
study population. This resulted in a small but significant difference in the duration of 
RA in the cases and the controls (+3 years in the cases). To take this difference into 
account, the lymphoma risk associated with different groups of accumulated 
inflammatory activity (high, moderate, low) was stratified for disease duration, 
which resulted in largely similar RRs of lymphoma. 
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Reverse causation 
A hematopoietic (or some other) malignancy can sometimes present with a clinical 
picture similar to RA or PsA (maybe less likely AS) for example oligo/polyartrthritis, 
high ESR or B-symptoms. This paraneoplastic phenomenon may be misclassified as 
incident RA or as some other inflammatory condition instead of the not yet diagnosed 
malignancy. Just as detection bias, reverse causation is likely to affect the risk 
estimates in studies with short follow-up time. To account for the possible effects of 
reverse causation, analyses in studies I, II and IV excluded all events and all person-
time the first 90 days of follow-up.  
  
External validity 
In study III the patient population consisted of hospitalized RA patients that were 
followed from 1964-1994. These observations are therefore not generalizable to RA 
patients diagnosed and treated today. By contrast, the patient population under 
study in studies I and II probably better reflects today’s RA patients, since this  
population consisted of incident RA patients with a rheumatologist based diagnosis 
according to the ACR criteria,[6] although a certain selection of patients, as already 
described, cannot be ruled out. The same is true for the findings in study IV, 
although the AS and PsA populations assembled from the outpatient register were 
less well defined compared with the RA population assembled from the SRQ.  
 
5.1.3 Precision 
Precision in epidemiologic measurements corresponds to the reduction of random 
error i.e. the influence of chance. Statistical techniques such as p values and 
confidence intervals can be used to quantify the degree of precision of observed 
estimates. The confidence levels were set to 95% in all studies. In the cohort studies 
(I-II, IV) the large cohort sizes contributed to enhance precision and to produce 
stable risk estimates in the analyses overall. However when an outcome is rare, such 
as assessing RRs per lymphoma subtype in study II, precision tended to be low 
despite the underlying large cohort size. This was also notable in the analyses of 
lymphoma risk in relation to inflammatory activity the first year following RA 
diagnosis in study II. However the observed tendency that higher inflammatory 
activity may be associated with an increased lymphoma risk is less likely due to 
chance alone as this finding corroborates previous reports.[197, 201] Due to sparse 
data in some of the analyses in study II and IV we abstained from calculating RRs 
when numbers of event were less than five. 
 
5.2 FINDINGS AND IMPLICATIONS  
Risk of lymphoma before diagnosis of RA and risk of cancer overall 
In study I we reported that a history of lymphoma or cancer overall was not more 
common than expected in RA patients compared with the general population. By 
studying the risk of lymphoma before diagnosis of RA we could reduce the impact of 
disease severity or accumulated burden of disease as well as other possible factors 
that influence the risk of lymphoma in established RA. Our results indirectly support 
that the major driving forces for lymphoma risk in RA are not shared genetic 
susceptibility or risk factors common for both diseases but instead points to RA 
disease-related factors or disease severity as important determinants behind 
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lymphoma development in RA. This is further supported by previous studies assessing 
overall occurrence of lymphomas in first-degree relatives of patients with RA which do 
not occur more often than expected.[148, 198, 244] 
 
On the other hand, in the light of the accumulation of lymphoma in a subset of RA 
patients [197,274] and the complex genetics of both diseases, our findings do not 
exclude that individual clustering due to shared genetic or common risk factors may 
be of importance for some particular lymphomas among a subset of RA patients. 
Given the study design, a true shared etiology between RA and lymphomas may still 
exist but may be confined to lymphomas diagnosed at high ages (i.e. with onset after 
the typical age at diagnosis of RA), to lymphomas with poor prognosis (i.e., had the 
patients survived the lymphoma, they would have gone on to develop RA), or to 
indolent lymphomas where repeated chemotherapy would prevent emerging RA from 
becoming clinically manifested. It may also be that an underlying genetic susceptibility 
exists but becomes important only in the presence of inflammation and/or in addition 
to immune-modulatory treatment.   
 
With respect to a history of cancer other than lymphoma in patients with newly 
diagnosed RA, we observed no increased risk overall, although we found an early 
increase in cancer risk following RA diagnosis, probably partly a consequence of 
cancer surveillance and detection around the time of RA diagnosis. Furthermore the 
risk increase was mainly driven by elevated risks for prostate and lung cancer 
whereas the risk for breast, colorectal and skin cancer was non-elevated. Our 
observation is generally consistent with results from other studies on RA and risk of 
cancer showing that RA patients are at increased risk of certain (but not all) types of 
cancer [188, 201-202, 275-276].  Apart from being important for patient counselling 
this may also be of etiological significance. In the therapy of several cancer forms, 
treatment such as chemotherapy and anti-hormonal therapy is often used. Our 
observation of a non-increased risk of RA following a diagnosis of a cancer may 
thereby suggest that perturbations induced by chemo- or anti-hormonal therapy are 
not major risk factors for RA. Conversely, one could speculate whether the effect of, 
for example, chemotherapy through apoptosis in various tissues could postpone or 
even prevent a later RA development.[277-278]  
 
Risk of lymphoma following RA diagnosis 
In studies I and II we observed that risk of malignant lymphoma remains increased to 
the same extent in incident RA patients diagnosed from 1997 up until 2010 as the one 
reported in historical cohorts [159, 190, 197, 199] (an approximately doubling of the 
expected risk). We also found a trend (although non-significant) that risk increases 
with disease duration. Furthermore, in study II we could not demonstrate any 
tendency towards declining risk in recent years when RA disease duration was taken 
into account. Given the radical changes in RA therapy and management over the last 
decade, with both earlier and more aggressive treatment [34], this observation is 
somewhat counterintuitive. There may be several explanations, but regardless of 
which, it is from a clinical point of view, important to point out that clinicians need to 
be aware of lymphoma development in RA patients. 
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One explanation may be that the therapeutic regimens may still not suppress 
accumulated inflammatory activity efficiently enough to decrease the lymphoma risk 
in RA. Studies I and II included RA patients diagnosed and treated in the late 1990’s, a 
time period where therapy standards were not as intense as in the last 5-10 years. On 
the other hand, in study I we observed a similar level of risk among RA patients 
diagnosed after 2000 as that reported for the entire study period 1997-2006. It is also 
important to emphasize that despite our efforts to monitor the risk for a sufficiently 
long time span, the follow-up period may still be too short to reveal a possible decline 
in the elevated lymphoma risk in recently diagnosed RA patients.  
 
In study II, our observation that a higher DAS28 (but not exposure to MTX or 
glucocorticoids) in the first year following RA diagnosis was associated with a higher 
lymphoma risk, adds some evidence for the role of chronic inflammation or the RA 
disease itself, rather than treatment, behind lymphoma development.[147, 154, 197] 
However, the results are limited by the decreasing availability of information on 
DAS28 with increasing disease duration in SRQ, i.e., we did not have the possibility to 
adjust for inflammatory activity during the entire RA disease duration which naturally 
would have been a better measure of disease severity. Despite this limitation, our 
result may serve as an indication that we need to be attentive to patients with high 
disease activity already early in their RA disease course. Regarding MTX, we found 
nothing to support that the treatment should be associated with an increased 
lymphoma risk in itself which is consistent with earlier data.[189, 197, 199]  
 
In regard of lymphoma risk in relation to exposure of TNFi (study II), we observed that 
TNFi-treated RA patients did not have any higher risk of lymphoma compared with 
patients not treated with TNFi (based on 6 exposed lymphomas). This is consistent 
with the increasing number of studies suggesting that TNFi therapy does not markedly 
increase the lymphoma risk in RA above the one already present (Table 6, section 
1.7.2.3)  
 
With respect to lymphoma subtypes (study II), we observed a higher proportion of 
DLBCL compared with that of the general population but still lower compared to the 
estimate previously reported from a Swedish historical RA cohort, in which DLBCL 
comprised almost 50% of all lymphomas (not including CLL).[197] An increased 
proportion of DLBCL has also been shown in other studies [154-155] with some 
exception.[204] Conversely, we found an increased proportion of HL and a decreased 
proportion of CLL compared with that of the general population. Previous data do not 
support any especially low or high proportion of CLL in RA. [154-155] As for HL, studies 
have typically shown a quite pronounced increased risk in RA.[190-191, 198, 200, 202-
203, 244] However, register-based studies spanning earlier time periods must be 
interpreted with caution as a significant proportion of NHL have been misclassified as 
HL which may inflate risk estimates of both HL and NHL.[76-77] This was however not 
the situation in study II in which we used the current WHO classification [73] and also 
(re)classified  the majority (40/45) of the identified RA lymphomas. One explanation of 
the low proportion of CLL among the RA lymphomas in study II may be that an 
incipient CLL may go undetected longer if masked by an alternative explanation for a 
mild leukocytosis such as treatment with oral glucocorticoids, and/or long-standing 
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inflammation. Alternatively, anti-rheumatic treatment (as already mentioned) may 
postpone or even prevent a CLL to emerge.[277-278] 
 
Furthermore, and important to emphasize, although a lower proportion of DLBCL than 
previously reported may suggest a less skewed distribution of lymphoma subtypes in 
contemporary RA, this is challenged by the observation of a higher than expected 
proportion of Hodgkin lymphoma. Thus we cannot exclude that the remaining 
increase in lymphoma risk is an effect of a switch from disease- to treatment-related 
lymphoma risks, i.e. that we have exchanged one lymphoma risk for another. This 
remains however a speculation.   
 
Oral glucocorticoids and risk of lymphoma 
In study III we found that oral glucocorticoids were associated with a decreased 
lymphoma risk in prevalent RA patients diagnosed 1964-1994. In study II we could to 
some extent confirm this finding as we noted a borderline risk reduction associated 
with treatment with oral glucocorticoids the first year after RA onset in incident RA 
patients diagnosed 1997-2010. In both studies, we were to some extent able to adjust 
for inflammatory activity; in study III for the entire RA course and in study II for DAS28 
during the first year following RA diagnosis. The consistency of our findings is 
interesting because the two RA cohorts vary widely with respect to study periods and 
therefore in RA disease control and use of anti-rheumatic therapies.  
As already discussed, evaluations of lymphoma risk in association with glucocorticoids 
in RA have been inconclusive [159, 209].  
 
Our observations in studies II and III suggest that not only may glucocorticoids be used 
safely (with respect to lymphoma risk) in RA patients; they may even have the 
potential to reduce the lymphoma risk in this patient population. Glucocorticoids have 
potent anti-inflammatory effects. Thus, the most obvious interpretation of our 
observation is that glucocorticoids efficiently lower inflammatory activity, the so far 
strongest risk factor for lymphoma in RA patients. This interpretation is supported by 
our observation of a particularly lowered lymphoma risk among those patients that 
received intra-articular glucocorticoids consistently as flare therapy (in study III), and 
the fact that adjustment for accumulated disease activity did not attenuate the 
association in studies II and III. A second explanation is that our finding is due to a 
better rheumatologic management rather than to properties of the glucocorticoids 
themselves. This is particularly relevant in study III where the study population 
consisted of “historical” RA patients not benefitting from today’s more proactive and 
guideline-based RA management. However, it is unlikely that this fully explains the 
results of study II, which included contemporary and more recently diagnosed RA 
patients receiving anti-rheumatic therapy to a large extent. 
 
A third explanation of the inverse association found is that the lymphoma “protective 
effect” of the glucocorticoids is mediated through other mechanisms than anti-
inflammatory properties.  Glucocorticoids induce apoptosis in immune cells including 
lymphatic cells [279-280] and are therefore used frequently in high doses in various 
lymphoma/leukemia regimens.[281] Whether this or a similar mechanism would 
apply also to the typically lower but longer glucocorticoid therapies used in RA is 
unclear, although successfully administered intra-articular steroids result in high 
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synovial exposure to glucocorticoids that in turn might "control" emerging clonal B-
cell populations. This remains, however, a speculation. If such a potential mechanism 
of the glucocorticoids is relevant for the development of lymphomas in non-RA 
patients remains unclear. 
 
AS/PsA and risk of lymphoma 
In study IV, we found that AS was not associated with an increased lymphoma risk 
overall. This finding is consistent with previously published studies.[148, 155, 205, 
248-249] The large AS cohort size assembled in our study enabled us to perform 
additional analyses with respect to DMARDs and oral glucocorticoids, as well as 
excluding patients ever recorded with a diagnosis code for RA. These sensitivity 
analyses did not appreciably change the results. 
 
For PsA, the interpretation of our results is more complex. Overall we found a 
borderline increased lymphoma risk of 20% compared with the general population 
although this risk disappeared when we excluded all patients in the PsA cohort ever 
recorded with a diagnosis code for RA. We further noted a significantly increased 
lymphoma risk restricted to PsA patients treated with DMARDs (defined as 
methotrexate and/or sulfasalazine), possibly reflective of a patient group where 
systemic treatment is indicated and thereby with a more severe disease. 
 
Clinically it is sometimes difficult to distinguish between RA and PsA, at least the PsA 
phenotype characterized by small-joint polyarthritis (as illustrated by the diagnostic 
uncertainty of the PsA diagnosis observed in our validation of the medical records). A 
significant proportion of patients with PsA (in study IV 17%) were at some occasion 
(correctly or incorrectly) diagnosed also as RA. Although the average RR of lymphoma 
approximated 1 when these patients were excluded, a truly increased lymphoma risk 
in a particular subset of PsA patients (i.e. those with an RA-like disease) is therefore 
difficult to rule out, as is a risk increase in those patients with the most severe PsA. 
Furthermore, based on the available information in study IV, we cannot exclude that 
the excess lymphoma risk seen in DMARD-exposed PsA patients is due to the DMARD 
treatment itself. Reports on the underlying lymphoma risk in PsA are few. A literature 
search resulted in one published study assessing cancer risk in prospectively followed 
PsA patients 1978-2004, reporting a non-increased SIR for all hematopoietic 
malignancies combined.[63] Our study is the first to our knowledge to assess 
lymphoma risk separately in PsA and adds an important baseline assessment of 
lymphoma occurrence in this population.  
 
The apparent discrepancy between increased risk of lymphoma in RA compared with a 
seemingly non-increased risk in AS and a potentially slightly increased risk in a subset 
of PsA may have several explanations. As already discussed, the underlying 
mechanisms behind lymphoma development in inflammatory conditions are complex. 
RA, unlike AS and PsA, is characterized by activated autoimmune and stimulated B 
cells. This together with systemic inflammation gives rise to a state of chronic immune 
stimulation, which is one of several possible biological mechanisms linking 
autoimmunity to lymphoma development. Another explanation may be that the 
accumulated burden of systemic inflammation is less pronounced in AS and PsA 
compared with RA.  
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With respect to treatment with TNFi, we found no increased lymphoma incidence 
rates in AS or in PsA after accounting for misclassification of RA as PsA.  As stated 
earlier, evaluations on lymphoma risks in AS and PsA following TNFi exposure are 
limited and risk assessments have been difficult due to the small number of events. 
[237-239, 260, 282]Thus, although study IV adds to the knowledge on this field and is 
the largest study (so far) to evaluate this association; we still did not have the power 
to assess robust risk estimates. It may also be that exposure to TNFi (or to 
combinations of therapies including TNFi) may lead to development of particular 
subsets of lymphoma. In recent years there have been unsettling reports on 
hepatosplenic T-cell lymphoma in young patients with IBD treated with a combination 
of TNFi and azathioprine.[257]  There is also some evidence of an increased 
proportion of in particular T-cell lymphoma in psoriasis.[155, 165, 253]  
 
In study IV, the distribution of lymphoma subtypes corresponded on average to the 
one expected in the general population, apart from a slightly higher proportion of 
DLBCL in AS (based on small numbers). By contrast, and reassuringly, there was no 
increased proportion of T-cell lymphoma neither in PsA nor in AS. 
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6 CONCLUSIONS 
             
i) A history of malignant lymphoma or cancer overall preceding the diagnosis of 
RA is not more common than expected in the general population.  
 
ii) The risk of malignant lymphoma remains increased in incident RA patients 
diagnosed during the last 5-10 years, and is similar in magnitude to that 
reported from historical cohorts.  
 
iii) With respect to risk determinants for future lymphoma development, high 
inflammatory activity during the first year following RA diagnosis may be of 
importance.  
 
iv) Treatment with oral glucocorticoids appears to be associated with a 
decreased lymphoma risk both in prevalent historical RA patients diagnosed 
1964-1994 and in incident more contemporary RA patients diagnosed 1997-
2010 treated with oral glucocorticoids during first year following RA 
diagnosis.  
 
v) The distribution of lymphoma subtypes in RA patients is different from that 
of the general population, with a smaller proportion of chronic lymphocytic 
leukemia and a higher proportion of Hodgkin lymphoma and diffuse large B-
cells lymphoma. 
 
vi) The average risk of lymphoma in AS and PsA is no different from the one in 
the general population, although an increased risk in a subset of patients 
with PsA cannot be excluded.  
 
vii) Regarding the RA, AS and PsA populations under study in this thesis, the 
occurrence of lymphoma was not more common in patients treated with 
TNFi than in TNFi-naïve patients. 
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7 FUTURE PERSPECTIVES 
 
Based on the findings in studies I-IV, some relevant future research questions are 
raised:   
 
i) What exact mechanisms are the driving forces behind the persistent lymphoma 
risk in contemporary RA patients? This may be addressed in studies with the 
possibility to abstract information on accumulated inflammatory activity and 
therapy during the entire RA disease course, thus ideally with a prospective 
approach. Such a study design should also include histopatological, genetic 
and molecular investigations of the lymphoma specimen, as well as samplings 
from sera and from inflamed tissue such as lymph nodes and synovial fluids. 
 
ii) Is the potential lymphoma “protective” effect of oral glucocorticoids restricted 
to RA patients or applicable also in other conditions? One way of approaching 
this would be to study the lymphoma occurrence in other conditions treated 
with longstanding and/or high doses of oral glucocorticoids.  
 
iii) Have today’s modern and more intense RA therapy regimens replaced one 
lymphoma risk for another? Future risk evaluations in RA (and other 
inflammatory conditions) following exposure to TNFi should not only focus on 
the lymphoma risk overall but also need to further characterize the lymphoma 
subtypes of these patients. 
 
iv) Is there an association with disease severity or longstanding chronic 
inflammation and lymphoma risk in PsA similar to what is seen in RA?              
This requires a study including information on disease activity/inflammatory 
activity and immune-modulatory therapy to be able to account for both 
potential treatment effects and the effect of disease severity on the lymphoma 
risk.  
 
v) What is the risk of lymphoma (or other co-morbidities) following exposure to 
TNFi in patients with AS and PsA? Reaching more reliable risk estimates on 
lymphoma risk in these patient populations may warrant international 
collaboration in order to assemble sufficiently large study populations given 
such a rare outcome as lymphoma. 
 
vi) What distinguish lymphomas in inflammatory conditions from the lymphomas 
in the general populations? One way to better understand the etiology behind 
lymphomas in inflammatory conditions may be to characterize the differences 
(or similarities) between the lymphoma tissues in patients with inflammatory 
conditions versus those without such a condition. This would preferably also 
include assessments of the levels and function of the B cells in order to better 
understand the impact of inflammation and the extent of a dysregulated 
immune system. 
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